Cover Page  for Protocol  
Sponsor name:  [CONTACT_48025], Inc. 
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  DCR -AUD -101 
Official title of study:  A Phase 1, Double -blind, Placebo -controlled, Single -
ascending -dose,  Safety, Tolerability, Pharmacokinetics, and 
Pharmacodynamics Study of DCR- AUD in Healthy 
Volunteers  
Document date *: 14-Mar-2022
*Document date refers to the date on which the document was most recently updated.
TITLE PAGE  
Protocol Title: A Phase  1, Double -blind,  Placebo -controlled,  Single -ascending -dose, 
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study 
of DCR -AUD in Healthy Volunteers  
Protocol Number:  DCR -AUD -101 
Compound:  DCR -AUD  
Study Phas e:  1 
Short Title:  Phase 1 SAD Study  of DCR -AUD in Healthy Volunteers 
IND Number:   152401  
Sponsor  Name:  [CONTACT_48025], Inc.  
[ADDRESS_50630] nue 
Lexington, MA [ZIP_CODE] US  
(617) 621 -8097
Version History: Original Protocol (version 1.0)  24-Jun-2021
Amendment 1 ( version 2.0)  09-Jul-2021
Amendment 2 (version 3.0)  19-Jul-2021
Amendment 3 (version 4.0)  26-Jul-2021
Amendment 4 (version 5.0)  28-Jul-2021
Amendment 5 (version 6.0)  14-Mar-2022
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 2 Sponsor  Signature [CONTACT_48026] : A Phase  1, Double -blind,  Placebo -controlled, Single -ascending -dose, Safety, 
Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR -AUD in 
Healthy Volunteers  
Protocol Number: DCR -AUD -101 
 
 
Version:   6.0 
Date:  14-Mar-2022  
 
 
 
Dicerna Pharmaceuticals, Inc.   Date  
  
Dicerna Pharmaceuticals, Inc.   Date  
   
Dicerna Pharmaceuticals, Inc.   Date  
 
  
DocuSign Envelope ID: 
16-Mar-[ADDRESS_50631] Information  
SAE Submission:  
(  Pharmacovigilance):  
24-hour Safety Telephone:
24-hour Safety Fax: 
email:   
Clinical Research Organization Medical Monitor:  
 
 
 
  
 
 
Sponsor  Medical Monitor:  
Dicerna Pharmaceuticals, Inc.  
 
 
 
 
 
Principal Investigator : 
 
 
  
[INVESTIGATOR_47933]: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 4 PRO TOCOL AMENDMENT SUMMARY OF CHANGES  
Amendment 5: 
Overall Rationale for the Amendment:  
The [ADDRESS_50632] of the interim 
analysis scheduled at the conclusion of Cohort 2, as emerging PD data did not dictate it was 
warranted. Other points of clarification for the timing and scheduling of study visits were also 
added . A summary of all changes is detailed i n the following table.   
Protocol Amendment 5 Summary of Changes  
Description of Change  Brief Rationale  Affected Sections  
Deleted requirement for interim 
analysis (IA) and clarified that one 
or more IA may be conducted if 
warranted, dictated by [CONTACT_47972] o f 
available clinical and/or 
biomarker/PD data.  Interim analysis may be done 
contingent on a possible 
safety or PD signal  in the 
emerging blinded data.  9.[ADDRESS_50633] 20  minutes before ECG, 
SEAS, vital signs, and facial 
temperature were recorded.  For clarity  1.3 Table 3, footnote “d”  DOCUMENT HISTORY  
Document  Date  
Amendment 5 (version 6.0)  14-Mar-2022  
Amendment 4 (version 5.0) 28-Jul-2021  
Amendment 3 (version 4.0)  26-Jul-2021  
Amendment 2 (version 3.0)  19-Jul-2021  
Amendment 1 (version 2.0)  09-Jul-2021  
Original Protocol  24-Jun-2021  
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 5 Description of Change  Brief Rationale  Affected Sections  
Changed diastolic blood pressure 
out-of-range limit from 55 to 
50 mmHg.  To expand the normal 
diastolic blood pressure range 
in healthy volunteers as low 
as 50 mmHg  5.1 Inclusion Criterion #7 
Updated the IP storage instructions 
from “ 2°C to 8°C ” to “at or 
below 30 °C; do not freeze”  and 
specified DCR -AUD should be 
warm ed for approximately 
1 hour before administration if 
stored at 2°C to 8°C . For clarity, based  on updated 
guidance from Technical 
Operations  6.2.2  Storage  
6.2.3  Preparation and Administration  
Clarified SRC review would 
include all available  safety data 
collected before expanding or 
escalating to the next dose.  To clarify  1.1.3  Overall Design  
2.3.1 Risks Related to siRNA 
 Molecules  
4.1 Overall Design  
9.6 Safety Review Committee, 
 Table  7 
Updated the pregnancy testing 
sensitivity range from “at least 
10 mIU/mL” to “25  mIU/mL”  To accommodate  local testing 
standards  10.4.[ADDRESS_50634] new version  Throughout the protocol  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50635] INFORMATION  ............ 3 
PROTOC OL AMENDMENT  SUMMARY OF CHANGES  ................................ .......................... 4 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 11 
1.1. Synopsis  ................................ ................................ ................................ ...................... 11 
1.1.1.  Rationale  ................................ ................................ ................................ ..................... 11 
1.1.2.  Objectives and Endpoints:  ................................ ................................ .......................... 12 
1.1.3.  Overall Design  ................................ ................................ ................................ ............ 12 
1.2. Overall Study Schema  ................................ ................................ ................................ 15 
1.3. Schedules of Activities  ................................ ................................ ............................... 16 
2. INTRODUCTION  ................................ ................................ ................................ ......20 
2.1. Study Rationa le ................................ ................................ ................................ ........... 20 
2.2. Background  ................................ ................................ ................................ ................. 20 
2.2.1.  Overview of Alcohol Use Disorder  ................................ ................................ ............ 20 
2.2.2.  Nonclinical Overview of DCR -AUD  ................................ ................................ ......... 21 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 22 
2.3.1.  Risks Related to siRNA Molecules  ................................ ................................ ............ 22 
2.3.2.  Risks Related to DCR -AUD Off -target Effects  ................................ .......................... 22 
2.3.3.  Risks Related to DCR -AUD Mechanism of Action  ................................ ................... 22 
2.3.4.  Risk Assessment  ................................ ................................ ................................ ......... 24 
2.3.5.  Benefit Assessment  ................................ ................................ ................................ .....24 
2.3.6.  Overall Benefit:Risk Conclusion  ................................ ................................ ................ 25 
3. OBJECTIVES AND ENDPOINTS  ................................ ................................ ............ 26 
4. STUDY DESIGN  ................................ ................................ ................................ .......27 
4.1. Overall Desig n ................................ ................................ ................................ ............ 27 
4.2. Scientific Rationale for Study Design  ................................ ................................ ........ 28 
4.3. Justification for Dose  ................................ ................................ ................................ ..28 
4.4. End of Study Definition  ................................ ................................ .............................. 29 
5. STUDY POPULATION  ................................ ................................ ............................. 30 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 30 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 7 5.2. Exclu sion Criteria  ................................ ................................ ................................ .......31 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 33 
5.4. Screen Failures  ................................ ................................ ................................ ............ 34 
6. STUDY INTERVENTION  ................................ ................................ ........................ 35 
6.1. Study Intervention(s) Administered  ................................ ................................ ........... 35 
6.1.1.  Dose Levels and Dose Escalation  ................................ ................................ ............... 35 
6.2. Preparation/Handling/Storage/Accountability  ................................ ............................ 36 
6.2.1.  Handling and Accountability  ................................ ................................ ...................... 36 
6.2.2.  Storage  ................................ ................................ ................................ ........................ 36 
6.2.3.  Preparation and Administration  ................................ ................................ .................. 36 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ........ 36 
6.4. Study Intervention Compliance  ................................ ................................ .................. 37 
6.5. Dose Modification  ................................ ................................ ................................ ......37 
6.6. Continued Access to Study Intervention After the End of the Study  ......................... 38 
6.7. Concomitant Therapy  ................................ ................................ ................................ .38 
6.7.1.  Rescue Medicine  ................................ ................................ ................................ ......... 38 
7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  ................................ .......39 
7.1. Participant Discontinuation/Withdrawal from the Study  ................................ ........... [ADDRESS_50636] to Follow up  ................................ ................................ ................................ ........ 39 
7.3. Cohort Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ 40 
7.3.1.  Dose Li miting Toxicities  ................................ ................................ ............................ 40 
7.3.2.  Electrocardiogram Findings  ................................ ................................ ........................ 40 
7.4. Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .40 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................ ...................... 41 
8.1. Efficacy Assessments  ................................ ................................ ................................ .42 
8.2. Safety Assessments  ................................ ................................ ................................ .....42 
8.2.1.  Physical Examinations  ................................ ................................ ................................ 42 
8.2.2.  Vital Signs  ................................ ................................ ................................ .................. 42 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ .....42 
8.2.4.  Alcohol Consumption via Timeline Follow Back  ................................ ...................... 43 
8.2.5.  Columbia -Suicide Severity Rating Scale  ................................ ................................ ....43 
8.2.6.  Mini -International Neuropsychiatric Interview  ................................ .......................... 43 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 8 8.2.7.  Clinical Safety Laboratory Assessments  ................................ ................................ ....43 
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting  ..................... 44 
8.3.1.  Time Period and Frequency for Collecting Adverse Event Information  .................... 44 
8.3.2.  Method of D etecting AEs and SAEs  ................................ ................................ .......... 45 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ ....................... 45 
8.3.4.  Regulatory Reporting Requirements for SAEs  ................................ ........................... 45 
8.3.5.  Pregnancy  ................................ ................................ ................................ ................... 45 
8.4. Treatment of Overdose  ................................ ................................ ............................... 46 
8.5. Pharmacokinetic s ................................ ................................ ................................ ........ 46 
8.6. Genetic s ................................ ................................ ................................ ...................... 46 
8.7. Pharmacodynamics  ................................ ................................ ................................ .....47 
8.7.1.  Ethanol Interaction  Assessments  ................................ ................................ ................ 47 
[IP_ADDRESS].  PD Biomarkers for EIA  ................................ ................................ .............................. 48 
[IP_ADDRESS].  Stoppi[INVESTIGATOR_47934]  ................................ ................................ .......................... 49 
[IP_ADDRESS].  Follow -up of Participants Who Continue to Have Positive Ethanol Reaction 
Symptoms at Da y 169  ................................ ................................ ................................ .49 
8.8. Immunogenicity Assessments  ................................ ................................ .................... 49 
8.9. Health Economics  ................................ ................................ ................................ .......49 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ .......50 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .50 
9.2. Sample Size Determination  ................................ ................................ ........................ 50 
9.3. Populations for Analyses  ................................ ................................ ............................ 50 
9.4. Statistical Analyses  ................................ ................................ ................................ .....50 
9.4.1.  General Considerations  ................................ ................................ ............................... 50 
9.4.2. Primary Endpoint(s)  ................................ ................................ ................................ ....51 
9.4.3.  Seco ndary Endpoint(s)  ................................ ................................ ................................ 51 
9.4.4.  Exploratory Endpoint(s)  ................................ ................................ ............................. 51 
9.4.5. Other Safety Analyses  ................................ ................................ ................................ 51 
9.5. Interim Analyses  ................................ ................................ ................................ ......... 52 
9.6. Safety Review Committee  ................................ ................................ .......................... 52 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ................................ ..54 
10.1.  Regulatory, Ethical, and Study Oversight Considerations  ................................ ......... 54 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 9 10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ......54 
10.1.2.  Financial Disclosure  ................................ ................................ ................................ ...54 
10.1.3.  Informed Consent Process  ................................ ................................ .......................... 54 
10.1.4.  Data Protection  ................................ ................................ ................................ ........... 55 
10.1.5.  Committees Structure  ................................ ................................ ................................ .55 
[IP_ADDRESS].  Safety Review Committee  ................................ ................................ .......................... 55 
[IP_ADDRESS].  Data Safety Monitoring Committee  ................................ ................................ ............ 55 
10.1.6.  Dissemination of Clinical Study Data  ................................ ................................ ........ 56 
10.1.7.  Data Quality Assurance  ................................ ................................ .............................. 56 
10.1.8.  Source Documents  ................................ ................................ ................................ ......56 
10.1.9.  Study and Site Start and Closure  ................................ ................................ ................ 57 
10.1.10.  Publication Policy  ................................ ................................ ................................ .......57 
10.2.  Clinical Laboratory Tests  ................................ ................................ ........................... 59 
10.3. Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ........................... [ADDRESS_50637]  ................................ ....................... 62 
10.3.4.  Recording and Follow -Up of AEs and/or SAEs  ................................ ......................... 63 
[IP_ADDRESS].  AE and SAE Recording  ................................ ................................ .............................. 63 
[IP_ADDRESS].  Assessment of Intensity  ................................ ................................ .............................. 64 
[IP_ADDRESS].  Assessment of Causality  ................................ ................................ ............................. 64 
[IP_ADDRESS].  Follow -up of AEs and SAEs  ................................ ................................ ....................... 65 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ ......65 
10.4.  Contr aceptive Guidance and Collection of Pregnancy Information  ........................... 66 
10.4.1.  Definitions  ................................ ................................ ................................ .................. 66 
10.4.2.  Contraception Guidance  ................................ ................................ ............................. 67 
10.4.3.  Pregnancy Testing:  ................................ ................................ ................................ .....68 
10.4.4.  Collection of Pregnancy Information  ................................ ................................ ......... 69 
[IP_ADDRESS].  Male Participants with Partners Who Become Pregnant  ................................ ............ 69 
[IP_ADDRESS].  Participants Who Become Pregnant  ................................ ................................ ........... 69 
10.5.  Genetics  ................................ ................................ ................................ ...................... 70 
10.6.  Liver Safety: Suggested Actions and Follow -up Assessments  ................................ ...71 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 10 10.7.  Abbreviations  ................................ ................................ ................................ .............. 73 
10.8.  Investigator Signature [CONTACT_3490]  ................................ ................................ ........................ 77 
10.9.  Protocol Amendment History  ................................ ................................ ..................... 78 
Amendment 5: 14-Mar-2022  ................................ ................................ ................................ ......... 78 
Amendment 4: 28 -Jul-2021  ................................ ................................ ................................ ........... 78 
Amendment 3: 26 -Jul-2021  ................................ ................................ ................................ ........... 78 
Amendment 2: 19 -Jul-2021  ................................ ................................ ................................ ........... 80 
Amendmen t 1: 09-Jul-2021  ................................ ................................ ................................ ........... 80 
11. REFERENCES  ................................ ................................ ................................ ........... 82 
 
Table of Tables  
 
Table  1: Schedule of Activities  ................................ ................................ ................................ .16 
Table  2: Allowed Windows for Collection of Plasma Pharmacokinetic Samples and 
for Complement Panel  ................................ ................................ ................................ 18 
Table 3: Schedule of Activities: Ethanol Interaction Assessments  ................................ .......... 19 
Table  4: Nonclinical Safety Margins for 5 -Week Repeat -dose Toxicity Studies  ..................... 29 
Table  5: Study Intervention Administered  ................................ ................................ ................ 35 
Table  6: Subjective Effects of Alcohol Scale (SEAS)  ................................ .............................. 48 
Table  7: Minimal Timing o f the Safety Review Committee Data Reviews  ............................. 53 
Table  8: Protocol -Required Safety Laboratory Assessments  ................................ ................... 60 
Table  9: Grading of Injectio n Site Reactions, CTCAE v 5.0  ................................ .................... 63 
Table  10: Highly Effective Contraceptive Methods  ................................ ................................ ...68 
Table  11: Liver Safety: Suggested Actions and Fol low-up Assessments  ................................ ...71 
 
 
Table of Figures  
 
Figure  1: Study Schematic for DCR -AUD -101 ................................ ................................ ......... 15 
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 11 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Phase  1, Double -blind, Placebo -controlled, Single -ascending -dose, Safety, 
Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR -AUD in Healthy 
Volunteers  
Short Title:   Phase 1  SAD  Study  of DCR -AUD in Healthy Volunteers  
1.1.1.  Rationale  
DCR -AUD is being de veloped for the treatment of alcohol use disorder (AUD) in adults using an 
RNA interference (RNAi ) technology platform. DCR -A1203 , the drug substance of DCR -AUD , 
is a synthetic double -stranded (hybridized duplex) RNA oligonucleotide conjugat ed to N-acetyl -
D-galactosamine (GalNAc) ligands that enable subcutaneous delivery of stable, safe, highly 
specific, and long -acting reduction  of mRNA in the liver via hepatic GalNAc carbohydrate 
receptors. The target of DCR -AUD is aldehyde dehydrogenase 2 (ALDH2 ), one of  the primary 
enzymes required for alcohol metabolism. Alcohol metabolism occurs predominantly in the liver  
via a [ADDRESS_50638]  AUD and account for its low prevalence in individuals  who are heterozygous 
or homozygous for  ALDH2  allele mutations . The magnitude  and duration of acetaldehyde 
accumulation is proportional to b oth the degree of ALDH2 enzyme inhibition (e.g., partial vs 
total) and the amount of alcohol consumed.  
DCR -AUD is designed to selectively reduce ALDH2  mRNA and ALDH2 activity in the liver, 
and ther eby [CONTACT_47973].  In 
cynomolgus monkeys, a single SC dose of 3 mg/kg DCR -AUD resulted in reduction of 
ALDH2  mRNA expression in liver up to [ADDRESS_50639] hum an study of DCR -AUD.  
The overall goals of this study are:  
1. To demonstrate that DCR -AUD single doses are  safe and well -tolerated  
2. To characterize the PK of single doses of DCR -AUD  
3. To chara cterize the PD of single  doses of DCR -AUD  and obtain safety data after alcohol 
exposure in adult healthy volunteers ( HVs) as assessed by [CONTACT_47974] s (EIAs) 
a. EIAs will be used to confirm target engagement. The degree of ALDH2 reduction  is 
measurable only after ethanol administration, v ia levels of plasma  acetaldehyde and 
acetate, and measurement of heart rate and facial skin temperature.  
b. The safety of ethanol i ngestion in the presence of DCR -AUD will be assessed during 
EIAs, each of which will b e followed by [CONTACT_47975] a 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 12 Phase 1 clinical  unit. The Investigator will not discharge any participant experiencing 
ongoing effects of ethanol a dministration until it is deemed medically safe to do so.  
c. Serial EIAs will be used to determin e the duration of action of DCR -AUD, so that an 
appropriate dose and dosing interval and safety monitoring plan for participants can 
be developed for later clinic al trials.  
1.1.2.  Objectives and Endpoint s: 
1.1.3.  Overall Design  
This is a 24 -week, randomized,  double -blind, placebo -controlled study  to evaluate  the safety, 
tolerability, PK, and PD of single -ascending doses (SAD)  of DCR -AUD administered to  adult 
HVs. 
Individual participants will be screened for a perio d of up to 28 days. Participants may undergo 
rescreening one time at the discretion of the Investigator or Sponsor . The single doses of 
DCR -AUD will be administered to adult HVs across 3 fixed ascend ing-dose cohorts (80 mg, 
240 mg, 480  mg) and 1 optional  cohort  (960 mg). Each  cohort  will comprise a sentinel group of 
3 participants  (2 active , 1 placebo ) who will be followed for the assessment of safety and 
tolerability and characterization of PK but wh o will not undergo  any EIAs.  The sentinel group  
will remain under observation in clinic until Day 4 (after dosing on Day  1) and will return to 
clinic on Days [ADDRESS_50640] evaluation s. The SRC will review 
available sentinel grou p safety data through the Day 15 assessments pr ior to authorizing cohort 
expansion within an individual cohort for the remaining 6  participants  (4 active , 2 placebo) . The 
6 participants in the expanded cohort will be followed for the assessment of safety a nd 
tolerability , characterization of PK , and assessment of PD (via EIA ). In addition to alcohol 
exposure on Day  –1 (prior to administration of study intervention) , these p articipants will 
undergo serial EIAs on Day 4 before being discharged from clinic on Day 5, and at 6 other times  
during the 24 -week study period. All EIAs will be conducted as in -clinic  assessments. Objectives  Endpoints  
Primary   
To evaluate the safety and tolerability of single doses of 
DCR -AUD administered to adult HVs  • Incidence and severity of AEs, SAE s, and DLT s  
• Changes from baseline in vital signs, 12-lead 
ECG , clinical lab oratory  tests, and p hysical 
examination findings  
Secondary   
• To characterize the PK of single doses of DCR -AUD  
in adult HVs • Plasma PK parameters of DCR -AUD  
• Urine PK parameters of DCR -AUD  
• To characterize the PD of single doses of DCR -AUD 
in adult HVs as assessed by [CONTACT_47976] • Change in PD biomarker s during standardized 
EIAs 
o Plasma  acetaldehyde , acetate, and EtOH  
o Heart rate and facial skin temperature  
o SEAS  
Abbreviations: AE: adverse event; DLT: dose -limiting toxicity; EIA: ethanol interaction assessment; EtOH: ethanol;  
HV: healthy volunteer; PD: pharmacodynamics ; PK: pharmacokinetic s; SAE: serious a dverse event; SEAS: Subjective 
Effects of Alcohol Scale  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50641]  positive ethanol reaction symptoms at the Day 169 EIA (e.g., nausea, 
vomiting , or substantial flushing ) will return ever y 28 (± 7) days f or follow -up EIAs until the 
positive ethanol reaction symptoms abate. The se conditional follow -up (CFU) EIAs will not 
require overnight admission to the clinic , but a ll other aspects of the EIA will be conducted  (see 
Table  3). Participants will be observed for  no less than  6 hours after ethanol administration and  
will not be discharged until the Investigator deems it medica lly safe to do so. 
If participants are not able to return to the site for assess ments or procedures because of 
COVID -19 or other exceptional circumstances, visits may be rescheduled or conducted  by 
[CONTACT_47977] -home telemedicine and/or home nursing visits at the 
discretion of the Investigator.   
All participant s will be given a diary to track AEs and temperance for the study duration. 
Participants  will be trained on the us e of the diary prior to discharge from the clinic  and will 
report on the diary at each in-clinic visit . 
The SRC will review  available  safety d ata from all participants in each cohort through at least 
the Day  15 assessments prior to authorizing dose escalation to the next cohort .  
The Study Schematic is presented in  Figure  1. The schedules of activities are  presented in 
Table  1 and Table  3.  
Intervention Groups and Duration : 
Doses of DCR -AUD to be administered will ascend from  80 mg in Cohort  1, to 240 mg in 
Cohort 2, to  480 mg in Cohort 3 , and to 960 mg in the optional Cohort  4. 
Individual participants will be screened for a period of up to 28 days. Randomization and 
administration with a single dose of study intervention will occur on Day 1. Participants will 
return to the site for safety, tolerability,  PK, and PD monitoring at specified time points as per 
the Schedule of Activities .  
Participants will be followed for 24 weeks (Day  169). 
Study Population:  
• Overtly healthy men and women aged 21 to 65  years  
• Social drinkers of modest  amounts (≤ 2 drinks/day and ≤ 3 days/week) who are able 
to refrain from drinking alcohol during the outpatient portion of the trial  
• Willing to participate in repeated low -dose EIAs  followed by [CONTACT_47978]  
• BMI 18.0 to 32.0 kg/m2 (inclusive)  
• No history of suicidal attempt as an adult , or suicid e ideation  in the past year that 
resulted in pharmacologic treatment  or hospi[INVESTIGATOR_059]. In addition, any history of 
severe or recent clinically significant depression, anxiety, bipolar disorder, 
schizophrenia, or other neuropsychiatric disorder that, in the judgment of the 
investigator, represents a safety risk to the indiv idual  were they to participate in the 
trial 
• No h istory of substance use disorder (including AUD) or illicit drug use (excluding 
cannabis) within  the preceding 12 months. Nicotine use is permitted  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101 Version 6.0, 14-Mar-2022  
 
 Page 14 • No history of delirium tremens or alcohol -related seizure s 
Treatment Blinding:  
This study will have multiple cohorts. Participants, Investigators, site staff  (excluding pharmac y 
staff) , the CRO staff , and the Sponsor Medical Monitor  will be  blinded to the randomization  of 
those cohorts . However, certain members of the Sponsor staff will be unblinded  to 
randomization for the duration of the study . Complete details will be present ed in the Study 
Blinding Pl an.  
Number of Participants:  
Up to 36 participants are planned to be enrolled in this study : 27 HVs in the 3 planned dose 
cohorts , plus an additional 9 HVs if the optional fourth  cohort is enrolled.  
Safety Review  Committee  and Data Safety Monitoring Commit tee: 
An SRC  will be convened to review  available  safety data at a predefined decision point  (Visit 2, 
Day 15) to ensure the safety of the participants in all cohorts. The scope of the review meetings 
will be defi ned in the SRC  charter. In the event that the SRC decide s to suspend or interrupt the 
study, a n independent  DSMC may be  convened to review the decision by [CONTACT_47979], resumed with no changes, or resumed with 
changes.   
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 
 Page 15 1.2. Overall Study Schema  
Figure  1: Study Schematic  for DCR -AUD -101 
 
 
Abbreviations: CFU: conditional follow -up; D: Day; EIA: ethanol interaction assessment; IMP: investigational medicinal product; pbo: placebo; SRC: Safety 
Review Committee; V: Visit  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 
 Page 16 1.3. Schedule s of Activit ies 
Table  1: Schedule of Activities  
 Screening  Visit 1 (In -Clinic ) V1ba Visit 2  Visit 3  Visit 4  Visits 5 -6 Visit 7  Visit 8  
EOS/ET  
Study Day  
Procedure/Assessment  -28 to -2 -1 1 2 3 4 8 15 
±2 day 29 
±2 day 57 
±2 day 85, 113  
±2 day  141 
±2 day  169 
±[ADDRESS_50642]-
dose  
Informed consent  X              
Clinical site admission/discharge b  X     X        
Inclusion/exc lusion criteria  X X X            
Demographic/baseline characteristics  X              
General medical history  X              
Psychological history  X              
C-SSRSc X X       X X  Xd  X 
MINI  X              
Alcohol history/consumption (TLFB)  X X      X X X X X X X 
Diary (AEs , temperance) 
distribut e/collect         X X X X X X X 
Drug/alcohol testing (urine, breath)  e X X       X X X X X X 
Testing for HCV, HIV, and HBV  X              
Randomize to study intervention    X            
Study intervention administration    X           
Medication history/concomitant meds  X X  X X X X X X X X X X X 
12-lead E CG f X X X X X X  X X X X X X X 
Vital signs  X X X X X X X X X X X X X X 
Physical examination  g  X X X  X X X X X X X X X X 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 
 Page 17  Screening  Visit 1 (In -Clinic ) V1ba Visit 2  Visit 3  Visit 4  Visits 5 -6 Visit 7  Visit 8  
EOS/ET  
Study Day  
Procedure/Assessment  -28 to -2 -1 1 2 3 4 8 15 
±2 day 29 
±2 day 57 
±2 day 85, 113  
±2 day  141 
±2 day  169 
±[ADDRESS_50643] (WOCBP only)  h X  X       X X X X X 
FSH (if applicable)   X              
Clinical safety laboratory tests i X X   X  X X X X X X X X 
Complement pan el j   X X X          
Blood sample for ADA   X        X    X 
SARS -CoV -[ADDRESS_50644] (at site)k  X        X X X  X 
Blood sample for genotypi[INVESTIGATOR_007]  l  X             
Plasma collection for PK analysis  m   X X X X X  X      
Urine collection for PK analysis  n    X X X X        
Ethanol inte raction assessment  o  X     X  X X X X  Xp 
Record AEs and SAEs q X X X X X X X X X X X X X X 
Abbreviatio ns: ADA: antidrug antibody; AE: adverse event; CFU: conditional follow -up; C-SSRS: Columbia -Suicide Severity Rating Scale ; ECG: electrocardiogram; EIA: 
ethanol interaction assessment ; FSH: follicle stimulating hormone; HBV: hepatitis B virus; HCV: hepatiti s C virus; HIV: human immunodeficiency virus;  ICF: informed 
consent form;  MINI: Mini -International Neuropsychiatric Interview; PK: pharmacokinetic ; SAE: serious adverse event ; SARS -CoV-2: severe acute respi[INVESTIGATOR_47935] 2 ; TLFB: Timeline Follow Back; WOCBP: women of childbearing potential  
a Visit 1b is only required for the [ADDRESS_50645] 6 hours before admission  on Day −1 and will receive  a standardized meal prior to the EIA . 
Participants  undergoing EIA will be d ischarged from the clinic on Day  5. Sentinel group participants will be discharged from the clinic on Day 4, following the 
72-hour PK blood draw and completion o f pooled urine collection.  
c At Scre ening, the ‘C -SSRS Baseline’ form will be administered, at all other visits indicated, the ‘C -SSRS Since Last Visit’ form will be administered.  
d C-SSRS to be administered only on Day 85.  
e Urine for drugs of abuse and breathalyzer for alcohol. Cannabis will not be recorded as a drug of abuse for t his study. Participants will be excluded from EIA 
evaluation that day if they test positive for  breath alcohol on day of study visit prior to EIA . 
f Standard ECGs will be performed 30 minutes predo se, and at 60 minutes  and 150 minutes postdose. A ±15 -minute window around each time point is allowed if 
multiple assessments are due. If multiple assessments are due, the order of priority should be ECG, vitals, PK, and then othe r assessments . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50646] for pregnancy (see Section  10.4). Loca l laboratory may be used. Pregnancy testing to be performed 
every 28 days throughout the study.  
i Hematology, clinical ch emistry, coagulation, and urinalysis samples will be collected at every visit in dicated. Only on Days −1, 4, 29, 85, and 169 will  
additional hematology analytes (mean corpuscular volume, mean corpuscular hemoglobin, mean co rpuscular hemoglobin concentratio n, and absolute and % of 
lymphocytes, monocytes, eosinophils, neutrophils, and basophils) be collected.  See Table  [ADDRESS_50647] of parameters  to be assessed . 
j During in-clinic stay at Day 1 and Day  2, blood samples will be collected for complement  predose, and at 2, 8, and 24  hours postdose . 
k Participants in ex panded cohorts will need to undergo SARS -CoV‑[ADDRESS_50648] void after study interventi on administration. Urine to be collected at intervals of 0 -4, > 4 -8, > 8 -12, 
> 12-24, > 24 -48, an d > [ADDRESS_50649] a sentinel group (n=3) that does not undergo any EIA assessment. For all other participants, all visits on which an EIA is cond ucted will 
require an overnight stay in the clinic. Participants will be admitted after an overnight fast a nd be provided a standar dized meal. EIA estimated time is 
~2.5 hours and is conducted at all visits except Visit  7 (Day  141). Note that the Day −[ADDRESS_50650] positive ethanol reaction  symptoms at the Day 169 EIA (e.g., nausea, vomiting , or substantial flushing) will return every  28 (±7) days for 
follow -up EIAs until the positive ethanol reaction symptoms abate. These CFU  EIAs will not require overnight admission to the clinic , but a ll other aspects of 
the EIA will be conducted . Particip ants will be observed for no less than [ADDRESS_50651] to  follow -up. 
 
Table  2: Allowed Windows for Collection of P lasma Pharmacokinetic Sa mples  and for Complement Panel  
Nominal Postdose Sample Time  Window  
15 minutes  ± 5 minutes  
30 minutes  ± 10 minutes  
1, 2, 4, 6, and 8 ho urs ± 15 minutes  
≥ 24 hours  ± 30 minutes  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 
 Page 19 Table  3: Schedule of Activities: Ethanol Interaction  Assessments  
 
Time in minutes  
Procedures  Pre-EIA Rest  Test Period  
− 20 0a 15 
±5 30 
±10 45 
±10 60 
±15 90 
±15 120 
±15 150 
±15 
Admit /return  to clinic (fasted 
state)b X          
Standardized mealc X          
Venous catheter placementd  X         
Alcohol consumptione   ← X →       
Blood biomarkersf g   X X X X X X X X 
EIA 12 -lead ECG g    X    X   X 
SEA S g,h    X  X  X X X X 
Facial skin temperatur e g i   X X X X X X X X 
EIA vital sign g j   X X X X X X X X 
Heart rate via telemetry    X X X X X X X X 
EIA AEsk   X X X X X X X X 
Abbreviations: AE: adverse event; CFU: conditional follow up;  ECG: electrocardiogram; EIA: ethanol interaction assessment ; 
EtOH: ethanol; SEAS: subjective effects of alcohol scale;   
a Time “0” is immediately before the first sip of alcohol. All Time [ADDRESS_50652] positive ethanol reaction symptoms at Day 169 ; these do not require  an overnight stay .  
c Participants are required to fast for at least [ADDRESS_50653] a venous access catheter placed for sample collection. Participant will be give n a ≥20-minute rest period 
following placement of the catheter prior to recording predose ECG, SEAS, vital signs, and facial temperature.  
e After completion of the standardized meal, alcohol will b e consumed in 4 aliquots over a 30 -minute period. The ethanol will be 
mixed in a liquid th at has no other alcohol, no caffeine, and is low in sugar. Because BAC is higher in women than men when 
given the same g/kg EtOH dose (~  15% higher mean BAC), the EtO H dose will be 0.4  g/kg for male participants and 0.34  g/kg 
for female participants. The t otal dose of EtOH will not exceed 28 g in men or 24 g in women.  
f Blood  samples will be collected via a ven ous access device for  biomarker  analysis, which  include acetaldehyde , acetate , and 
ethanol . Blood  sample  collection and processing will be detailed in the Laboratory Manual.   
 g The order of assess ments should be blood draw , 12-lead EC G, SEAS , vital signs , and facial temperature . 
,h Participants will rate the extent to which they are feeling each of the 14 SEAS effects in the present moment.  
 i Facial skin temperature will be measured using a surface scanning thermometer and will be collected prior to blood draws.  
 j Vital sig ns wi ll be recorded prior to blood draws and include blood pressure and pulse/heart rate.  
k Adverse events associated with administration of ethanol will be recorded continuously throughout the tes t period, beginning 
with the first sip of alcohol.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 20 2. INTRODUCTION  
2.1. Study Rationale  
DCR -AUD is being developed for the treatment of AUD in adults using an RNAi  technology 
platform. DCR -A1203, the drug substance of DCR -AUD, is a synthetic double -stran ded 
(hybr idized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific 
hepatic access and uptake after subcutaneous administration. Once inside the hepatocyte, the 
antisense sequence of DCR -AUD is designed to target and reduce the ex pression  of 
ALDH2  mRNA in the liver . 
The target of DCR -AUD is ALDH2 , one of the primary enzymes required for alcohol 
metabolism. Alcohol metabolism occurs predominantly in the liver via a [ADDRESS_50654]  AUD and account for its low prevalence 
in individuals  who are heterozygous or homozygous for  ALDH2  allele mutations . The magnitude 
and duration of acetaldehyde accumulation is proportional to both the degre e of ALDH2 enzyme 
inhibition (e.g., partial vs total) and the amount of alcohol consumed.  
Study DCR -AUD -[ADDRESS_50655] study of DCR -AUD in humans. The aims of the study are to 
evaluate the safety and tolerabi lity of single -ascending -doses of DCR -AUD and to characterize 
its PK profile and PD effects.  
2.2. Background  
2.2.1.  Overview of Alcohol Use Disorder  
Alcohol  use disorder  is a chronic condition characterized by [CONTACT_47980], loss of 
control over alcohol use, and a negative emotional state when not using alcohol. A range of 
medical, psychological, social, economic, and personal problems  are associated with AUD . 
Diagnosis is defined as meeting ≥ 2 of 11 criteria in the Diagnostic and Statistical Manual of 
Mental  Disorders -5 (DSM 5) during the same 12 -month period. A survey of over 36,000 adults 
found AUD had a 12 -month prevalence of 13.9% adults in the US in 2013  (Grant  et al., 2015 ). 
AUD often goes untreated, possibly due to the  lack of adequate treatment options. It is est imated 
that <  10% of US adults with AUD seek help or treatment, and that similarly low percentages of 
those treated receive pharmacotherapy ( Grant et al., 2015 ; National Survey on Drug Use, 2014 ; 
Litten et al., 2014 ; Han et al., 2015 ; Knudsen  et al., 2011 ).  
There are 3 FDA -approved medications for AUD: disulfiram, oral and lon g-acting injectable 
naltrexone, and acamprosate. However, many individuals show limited or no response to these 
drugs, with poor compliance a factor ( EMA, 2010 ; Gastfriend, 2014 ; Chick et al., 1992 ; 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 21 Jørgensen et al., 2011 ; Bryson et al., 2011 ). Thus, there remains an u nmet need for an effective 
AUD treatment.  
2.2.2.  Nonclinical Over view of DCR -AUD  
The pharmacology of DCR -A1203 was characterized in in vivo studies in mice and monkeys to 
demonstrate the ability to reduce levels of the hepatic ALDH2  mRNA. The potential for off -
target gene silencing was assessed using in silico evaluatio n of the human transcriptome. The 
sequence is conserved in mouse, monkey, and human and therefore, DCR -A1203 is active in 
both nonclinical species evaluated. In addition, a stand -alone  comprehensive  safety 
pharmacology study in cynomolgus monkeys was condu cted.  
Overall, the data support the hypothesis that DCR -A1203 has potential to yield meaningful and 
robust clinical responses across the AUD patient populations based upon the followin g:  
• A single SC dose of up to 100  mg/kg in mice resulted in a dose -depe ndent decrease in 
Aldh2  mRNA expression in liver, persistent for 14  days postdose, followed by 
[CONTACT_2715]-dependent recovery.  
• Following a single 3 mg/kg SC dose of DCR -A1203, liver ALDH2 mRNA  expression 
levels were reduced by >  75% in cynomolgus monkeys, with th e nadir at 28 days 
postdose , and > 50% reduction in ALDH2 mRNA expression up to  112 days 
postdose.  
• Repeat SC administration of DCR -A1203 up to 300  mg/kg resulted in significant 
reductio n of hepatic Aldh2  mRNA in mice (>  97%) and hepatic ALDH2  in monkeys 
(> 85.9%).  
• Based on in silico analysis, potential off -target complementarities with [ADDRESS_50656] been conducted at doses up to 300  mg/kg for up 
to 5 weeks in mice and monkeys. DCR -A1203 has been evalua ted for potential gen otoxicity in a 
bacterial reverse mutation assay and an in vitro micronucleus study.  
• DCR -A1203 administration had no adverse effects on cardiovascular , respi[INVESTIGATOR_696], or 
central nervous system function in conscious, radiotelemetry -implan ted cynomolgus 
monkey s following a single SC injection of up to 300  mg/kg.  
• The administration of DCR -A1203 to mice and monkeys in the 5 -week repeat -dose 
studies resulted in no DCR -A1203 -related, adverse findings. The NOAEL in the 
mouse and monkey repeat -dose toxicity studies w as considered by [CONTACT_47981] 300 mg/kg, the highest dose level administered. Based on input from the FDA 
regarding clinical pathology and histopathology in a single 300 mg/kg animal in the 
monkey study, a more conservative  approach is being ta ken, and the mid -dose of 
100 mg/kg is being treated as the NOAEL for the purpose of determining a safety 
margin for the monkey study . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 22 • DCR -A1203 was not genotoxic in the bacterial reverse mutation and in vitro 
micronucleus assays.  
Overa ll, the nonclinical safety program of DCR -A1203 did not identify any major safety issues.  
A detailed description of the chemistry  and pharmacology of DCR -AUD is provided in the 
Investigator’s Brochure .  
2.3. Benefit/Risk Assessment  
The summary of potential  risks provided below is based  on an in -depth review of literature 
relating to the proposed approach and insig hts from the nonclinical pharmacology and toxicology 
studies.  
2.3.1.  Risks Related to siRNA Molecules  
The potential risks associated with  DCR -AUD  are lim ited to the risks associated with the siRNA 
oligonucleotide portion of the drug product.  
To date, DCR -A1203 has been associated with no adverse effects in nonclinical studies. Clinical 
experience in more than 200 patients and HVs with the Dicerna GalXC™ platfor m suggests a 
favorable  safety profile with little -to-no evidence of systemic immune stimulation or toxicities. 
Mild, self -limiting injection site reactions have been reported (Dicerna data on file).  
As part of the study’s planned mitigation strategy , each cohort will comprise a sentinel group of 
3 participants (2  active, 1  placebo)  who will be followed for the assessment of safety and 
tolerability and characterization of PK. Sentinel participants will not undergo EIA tests. The 
sentinel group will remain u nder observation in clinic until Day 4 (after dosing on Day 1) and 
will return to clinic on Day [ADDRESS_50657] evaluation s. The SRC 
will review available sentinel group safety data , including the safety laboratory result s, through 
the Day 15 assessments and PK through 72 -hours postdose prior to authorizing cohort expansion 
for the remaining 6 participants, who will undergo EIA tests.  
All study participants will be monitored for signs or symptoms of systemic toxicity, dec line in 
liver or kidney function, abnormalities on hematologic parameters (including platelets and 
coagulation parameters), and abnormalities in vital signs, ECGs, complement activation, or other 
relevant safety parameters . 
2.3.2.  Risks Related to DCR -AUD  Off-target E ffects  
The antisense sequence of DCR -AUD is designed to target and reduce the expression of ALDH2  
mRNA in the liver. Potential off -target complementarities  at the level of a single mismatch were 
completely absent from the human transcripts analyzed  in in silico studies . These findings 
demonstrate that DCR -AUD has a high degree of specificity for the ALDH2 mRNA. The 
sequence is conserved in mouse, monkey, and human, and therefore, DCR -AUD is active in all 
nonclinical species evaluated . 
2.3.3.  Risks Related to DCR -AUD Mechanism of Action  
DCR -AUD is designed to induce intolerance to high -intake alcohol consumption 
(e.g., ≥ 4 drinks/occasion in men; ≥  3 drinks/occasion in women)  by [CONTACT_47982]2  mRNA and ALDH2 activity in the liver, and thereby [CONTACT_47983]: 

Dicerna Protocol DCR -AUD -[ADDRESS_50658] been documented with 
disulfiram treatment  and in individuals who are homozygous for  ALDH2 -gene –inactivating 
mutations  compared with ALDH2  mutation heterozygotes, proportional to the magnitude of 
systemic ALDH2 inactivation . 
Study participants will be clearly informed of these potential risks. Symptoms that develop with 
concomitant alcohol consumption are expected t o be self-limited and manageable  with 
supportive care and can be avoided  by [CONTACT_47984] . 
In the absence of direct measurement of ALDH2 activity in the liver (e.g. , via liver biopsy), 
EIA assessments are necessary to evaluate  and confirm DCR -AUD PD activity. The 
EIA interventions in this protocol are designed to minimize the  amount of alcohol to be 
administered  (approximately 0.4  g/kg, equivalent to 1 -2 drinks over a 30-minute period  in a 
70 kg person) , and the signs and sympt oms of  alcohol intolerance .  
  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 24 2.3.4.  Risk Assessment  
Potential Risk of Clinical 
Significance  Summary of Data/  
Rationale for Risk  Mitigation Strategy  
FIH study  Standard FIH methodology for 
testing and analysis  Study will be conducted under 
close observation in a clinical 
Phase  1 study unit.  
Study Intervention : DCR -AUD  
Dose selection  (unknown human 
safety and tolerability)   The dose range proposed for this 
study is justified based on the  
safety profile of such doses in 
nonclinical toxicity studies  Sequential do se escalation ; use of 
sentinel  dose group  in each cohort ; 
SRC  to review safety and PK and 
approve dose selection and dose 
escalation . 
Potential risk of DLT  or other 
safety signals  This is a FIH study and the clinical 
safety profile has not yet been 
establ ished  SRC may convene a D SMC to 
adjudicate DLT or safety signal s 
Potential immune stimulation  via 
the complem ent cascade  Previously seen in highly 
phosphorothioated  oligonucleotides  Monitoring of complement factor s 
within 24 h ours of dosing   
Study Proced ures 
EIA: alcohol administration is 
expected to cause unpleasant effects 
in participants receiving active  
DCR -AUD  
 Required to assess and confirm 
DCR -AUD PD activity, including 
magnitude and duration of 
concomitant alcohol interaction  Alcohol to be admini stered  
gradually  in EIA  and perform ed in 
a Phase  [ADDRESS_50659]-administration  in-clinic  
overnight  observation .  
Enroll participants who are tolerant 
to amount of ethanol to be 
administered in the EIAs  
(approximately 0.4 g/kg, equivalen t 
to 1-2 drinks over a 30 -minute 
period in a 70 kg person )  
Other  
Prolonged PD activity of 
DCR -AUD  may cause alcohol 
intolerance for up to [ADDRESS_50660] (s) resulting from 
high levels of alcohol intake  during 
DCR -AUD  treatment is an 
intentional design element  of the 
DCR -AUD target product profile 
and predicted  based on  the core  
RNAi/GalXC drug platform.   
The c linical significance is 
expected to be limited to high or 
very high alcohol  consumption, but 
adverse effects may occur at lower 
amounts , including incidental 
exposures.  Ensure risks related to DCR -AUD 
potenti al PD effects and duration 
are clearly communicated in the  
informed consent.  
Adverse effects related to alcohol 
consumption are self -limited, 
reversible, and avoidable.  
Added CFU (s) for any participant  
who has positive ethanol reaction 
symptoms  (e.g., nausea, vomiting, 
or substantial flushing) at the 
Day 169 EIA, until the symptoms 
abate.  
2.3.5.  Benefit Assessment  
There is no expected benefit for HV participants in the study . Data generated in this study will  
contribut e to the  develop ment  of a potential n ew therapy for  AUD , an area of significant unmet 
medical need , and FDA -approved treatment options . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 25 RNAi -mediated  reduction  of ALDH2  via DCR -AUD is designed to offer significant safety 
advantages relative to agents such as disulfiram, which inhibits multiple aldehy de 
dehydrogenases as well as other enzymes ( Koppaka et al., 2012 ). siRNA -mediated reduction  will 
only target  ALDH2  in the liver , leaving other aldehyde dehydrogenases able to function. Further , 
DCR -AUD  reduction  of ALDH2  will be liver -specific, leaving non -liver ALDH2 unaffected . 
Thus, the target phenotype of DCR -AUD  treatment is expected to be more analogous to that in 
individuals who are heterozygous for ALDH2  mutations and demonstrate an intermediate alc ohol 
intoleranc e phenotype (i.e., fewer, milder symptoms at low levels of alcohol intake).  
2.3.6.  Overall Benefit:Risk Conclusion  
With  the measures planned  to minimize participant  risk in this study, the potential risks 
identified in association with DCR -AUD  are justified by [CONTACT_3433] e anticipated benefits that may be 
afforded to patients  with AUD . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 26 3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
To evaluate the safety and tolerability of single 
doses of DCR -AUD administered to adult HV s  • Incidence and severity of AE s, SAE s, and DLT s  
• Changes from baseline in vital signs, 12 -lead 
ECG, clinical laboratory tests, and physical 
examination findings  
Secondary   
• To characterize the PK of single doses of 
DCR -AUD in adult HV s • Plasma PK parameters of DCR -AUD  
• Urine PK parameters of DCR -AUD  
• To characterize the PD of single doses of 
DCR -AUD in adult HV s as assessed by 
[CONTACT_47985] s • Change in PD biomarker s during standardized 
EIAs 
o Plasma  acetaldehyde , acetate , and EtOH  
o Heart rate and facial skin temperature  
o SEAS  
Abbreviations:  AE: adverse event; DLT: dose -limiting toxicity; EIA: ethanol interaction assessment; EtOH: ethanol; HV: 
healthy volunteer; PD: pharmacodynamics; PK: pharmacokinetic; SAE: serious adverse event ; SEAS: Subjective Effects of 
Alcohol Scale   
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 27 4. STUDY DESIGN  
4.1. Over all Design  
This study is a 24-week, randomized, double -blind, placebo -controlled , single -ascending -dose 
study to evaluate the safety, tolerability, PK, and PD of DCR -AUD in adult HVs. The overall 
goals of this study are:  
• To demonstrate that DCR -AUD single  doses are  safe and well -tolerated  
• To characterize the PK of single doses of DCR -AUD  
• To characterize the PD of single doses of DCR -AUD  and obtain safety data after 
alcohol exposure in adult healthy volunteers ( HVs) as assessed by [CONTACT_47986] s (EIAs) 
Individual participants will be screened for a period of up to 28 days. Participants may undergo 
rescr eening one time at the discretion of the Investigator or Sponsor . Single doses of DCR -AUD 
will be administered to adult  HVs across 3 fixed ascending -dose cohorts (80 mg, 240  mg, 
480 mg) and 1  optional cohort (960  mg), each to include up to 9 participants/dose cohort 
(6 active and 3 placebo). Each p articipant will receive  a single dose of DCR -AUD (or matching 
placebo) on Da y 1. Participants will be observed to allow collection of data up to 24 weeks  after 
administration  of study intervention  (Day 169).  
Each cohort  will comprise a sentinel group of 3  participants  (2 active , 1 placebo ) who will be 
followed for the assessment of safety and tolerability and characterization of PK but who will not 
undergo any EIAs. The sentinel group will remain under observation in clinic until Day 4 (after 
dosing on Day  1) and will return to clinic on Day s [ADDRESS_50661] 
evaluation s. The SRC will review available sentinel group safety data through the Day 15 
assessments prior to authorizing cohort expansion within an individual cohort for the remaining 
6 participants ( 4 active , 2 placebo) . 
The 6 s tudy participants in the expanded cohort  will undergo EIAs  to evaluate the PD effects of 
ALDH2  reduction  by [CONTACT_47987] -AUD , which includ e plasma  acetaldehyde , acetate , and ethanol ; heart 
rate; facial skin temperature , and subjective feelings of alcohol intoxication or intolerance usin g 
the Subjective Effects of Alcohol Scale ( SEAS ; Table  3). All visits on which an EIA is 
conducted will require participants  to check into the clinic after a 6-hour fast. Participants  will be 
fed a standardized meal  in the clinic prior to the EIA  and will be admitted  for an overnight stay 
in the Phase  1 telemetry unit . Participants  will return t o the site for safety, tolerability, PK , and 
PD monitoring  (via serial EIAs ) throughout the 24-week double -blind study period , as specified 
in Table  1. Participants who have positive ethanol reaction symptoms at the Day 169 EIA 
(e.g.,  nausea, vomiting , or substantial flushing ) will return every 28 (±7) days for follow -up EIAs 
until the pos itive ethanol reaction symptoms abate. These CFU EIAs will not require overnight 
admission to the clinic, but a ll other aspects of the EIA will be conducted  (see Table  3). 
Participants will be observed for no less th an 6 hours after ethanol administration and will not be 
discharged until the Investigator deems it medically safe to do so.  
Cohort expansion will require SRC review of available Day 15 safety data for all partic ipants in 
the sentinel group before the remai nder of the  cohort can be enrolled . Dose escalation w ill 
require SRC review of  available safety data , including the safety laboratory values,  for all 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50662] Day  15 before the sentinel grou p of the next cohort can be enrolled  
(Section  9.6). 
Individual participants will be screened for a period of up to 28 days. Screening assessments will 
include a psychological history and a history of alcohol consumption using the TLFB method to 
identify participants who are HVs and meet  the minimum inclusio n/exclusion alcohol 
consumption requirements . TLFB is a validated method to retrospectively assess  drinking 
behavior history . Randomization and administration of study intervention will occur on Day  1. 
If participants are not able to return to the site for  assessments or procedures because of 
COVID -19 or other exceptional circumstances, visits may be rescheduled or conducted by 
[CONTACT_47977] -home telemedicine and/or home nursing visit s at the 
discretion of the Investigator.   
All part icipants will be given a diary to track AEs and temperance for the study duration. 
Participants will be trained on the use of the diary prior to discharge from the clinic  and will 
report on the diary at each visit.  
4.2. Scientific Rationale for Study Design  
SAD testing in a single sequential Phase  1 study design has been successfully used  to determine  
dose tolerability and PK/PD measurements. The Sponsor’s proposed Phase  1 study takes this 
approach . Further, the use of sentinel participants is intended  to ensure safe, well -tolerated doses 
of DCR -AUD are used.   
Study participants will undergo EIAs to evaluate the PD effects of ALDH2  reduction  by 
[CONTACT_47987] -AUD  and obtain safety data regarding alcohol exposure in adult HVs  during concomitant 
alcohol consumption . Participants  will be administered alcohol  on Day  –1 (prior to 
administration of study intervention) to establish a baseline for biomarker assessments and 
evaluate eligibility . Following administration of study inter vention , participants  will be 
administered serial EIAs , as specified in Table  1.  
• EIAs will be used to confirm target engagement. The degree of ALDH2 reduction  is 
measurable on ly after ethanol administration, via lev els of plasma  acetaldehyde and 
acetate, and measurement of heart rate and facial skin temperature.  
• The safety of ethanol ingestion in the presence of DCR -AUD will be assessed during 
EIAs, each of which will be follow ed by [CONTACT_47988] a 
Phase 1 telemetry unit. The Investigator will not discharge any participant 
experiencing ongoing effects of ethanol administration until it is deemed medically 
safe to do so.  
• Serial EIAs will be used to determi ne the duration of action of DCR -AUD, so  that an 
appropriate dose and dosing interval and safety monitoring plan for participants can 
be developed for later clinical trials.  
4.3. Justification for Dose  
The initial dose levels to be administered were determined following evaluation of nonclinical 
PK/P D and safety data ( FDA, 2005 ) and will ascend from 80  mg in Cohort  1, to 240  mg in 
Cohort 2, to 480  mg in Cohort 3, and 960  mg in the optional Cohort  4. 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 29 Safety margins for DC R-A1203 were determined using the HEDs of the dose levels for the 
5-week toxicity studies. The NOAEL in the mouse and monkey repeat -dose toxicity studies was 
considered  by [CONTACT_47989]  300 mg/kg, the highest dose level administered. Based on 
input from the FDA regarding clinical pathology and h istopathology in a single 300 mg/kg 
animal in the monkey study, a more conservative approach is being ta ken, and the mid -dose of 
100 mg/kg is being treated as the NOAEL for the purpose of determining a saf ety margin for the 
monkey study.  The monkey is the more relevant species due to a greater homology with the 
human transcriptome, allowing for assessment of on - and off -target effects  (Cooper et al ., 2003).  
For the planned  starting flat dose of 80 mg, the exposure multiple  relative to the monkey HED 
for 100 mg/kg would be 28 -fold. For the planned high dose of 960 mg, the exposure multiple 
relative to the monkey HED for 100 mg/kg would be 2 -fold (Table  4). 
Table  4: Nonclinical Safety Margins for 5 -Week Repeat -dose Toxicity Studies  
Species  Dose  
(mg/kg)  HED a 
(mg/kg)  Exposure Multiple 
Relative to 80 -mg  
Clinical Dose b Exposure Multiple 
Relative to 960 -mg 
Clinical Dose b 
Mouse  
30 2.4 2 0.2 
Monkey  9.7 8 0.7 
Mouse  
100 c 8.1 7 0.6 
Monkey  32.3 28 2 
Mouse  
300 c 24.4 21 2 
Monkey  96.8 85 7 
Abbreviations: HED = human equivalent dose  
a The HED is based on the Guidance for Industr y: Estimating the Maximum Safe Starting Dose in Initial Clinical 
Trials for Therapeutics in Adult Healthy Vo lunteers (FDA, 2005).  
b A 70 -kg human is used for determination of mg/kg for clinical dos e and margin determination  
c The NOAEL in the mouse and monkey repeat -dose toxicity studies was considered by [CONTACT_47990] 
300 mg/kg, the highest dose level administered. Based on input  from the FDA regarding clinical pathology and 
histopathology in a single 300 mg/kg animal in the monkey study, a more conservative approach is being taken, 
and the mid -dose of 100 mg/kg is being treated as the NOAEL for the purpose of determining a safety  margin for 
the monkey study  
4.4. End of Study  Definition  
A participant is considered to have completed the st udy if he/she has completed all phases of the 
study , including the last scheduled procedure shown in the SoA (Section  1.3). 
The end of the study is defined as the date of the last visit of the last participant in the study.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 30 5. STUDY POPULATION  
Up to 36 HV participants are planned to be enrolled in this study: [ADDRESS_50663] amounts (≤ 2 drinks/day and ≤  3 days/week) who are able  to 
refrain from  drinking  alcohol dur ing the outpatient portion  of the trial . 
4. Negative screen for drugs of abuse (to include at minimum: amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_2438] , and benzodiazepi[INVESTIGATOR_1651]) at Screening and Day 1. Cannabis will not be 
recorded as a drug of a buse for this study .  
5. Willing to participate in repeated l ow-dose EIAs followed by  [CONTACT_47978]  (see 
Table  1). 
6. Has a negative test for SARS -CoV -2 infection on Day  −1 and prior to  admission to the 
clinical unit . (Refer to Study Manual for details on the timing of SARS -CoV -2 testing.)  
7. Systolic BP in the range of 90 to 140 mmHg and diastolic BP in the range of 50 to 
95 mmHg . 
Sex and Childbea ring Potential  
8. Male or femal e 
• Male participants with partners of childbearing potential must agree to use 
contraception from Screening through at least [ADDRESS_50664] dose of study 
intervention and refrain from donating sperm during this period  (see Section  10.4). 
• Female participants may not be pregnant or breastfee ding, and at least one of the 
following conditions must apply:  
− Is not a woman of childbearing potential (WOCBP) or  
− If a WOCBP, must agree to follow the contraceptive guid ance (see Section  10.4), 
beginning  at consent and the first Screening visit and for at least [ADDRESS_50665] dose of study intervention.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 31 Weight  
9. BMI within the range 18.0 to 32.0 kg/m2 (inclusive).  
Informed  Consent  
10. Capable of giving signed informed consent, which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol.  
5.2. Exclusion Criteria   
Participants are excluded from if any of the following criteria apply:  
Medical Condition s 
1. History of any medical condition that may interfere with the absorption, distribution, or 
elimination of study intervention , or with the clinical and laboratory assessments in this 
study, including (but not limited to): chronic or recurrent rena l disease , functional bowel 
disorders (e.g., frequent diarrhea or constipation), clinically significant cardiovascular or 
pulmonary disease or has cardiovascular or pulmonary disease requiring pharmacologic 
medication, GI  tract disease, pancreatitis, seizu re disord er, mucocutaneous , or 
musculoskeletal disorder . NOTE: Persons with clinically stable asthma who have not 
been ho spi[INVESTIGATOR_47936] .  
2. History of suicidal attempt  as an adult  or suicid e ideation  in the past year that resulted in 
pharmacologic treatment  or hospi[INVESTIGATOR_059].  Specifically:  
• Answer of “yes” on items  4 or 5 of the Suicidal Ideation section of the C -SSRS at 
screening if ideation occurred in the previous 6  months.  
• Answer of “yes” on any item of the Suicidal Behavior section of the C -SSRS, except 
for the Non -Suicidal Self -injurious Behavior if this behavior occurred in the previous 
2 years.  
3. Any history of severe or recent  clinically significant depression, anxiety, bipolar disorder, 
schizophrenia, or other neuropsychiatric disorder that, in the judgment of the Investigator, 
represents a safety risk to the individual were they to participate in the trial , as informed 
by [CONTACT_47991]’s  medical history and/or respons es to the MINI Screen Questionnaire . 
4. History of delirium tremens or alcohol -related seizures .  
5. History of significant adverse reaction (s) to alcohol . 
6. Any condition that, in the opi[INVESTIGATOR_689], would make the participant 
unsuitable for particip ation or could interfere with participation in or completion of the 
study including : 
a. Poorly controlled or unstable hypertension  
b. Clinically significant abnormalities in vital signs: pulse rate  (< 40 or >  90 bpm) , 
respi[INVESTIGATOR_697], or temperature  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 32 c. Clinically  significant abnormalities in 12 -lead ECG at Screening or predose on Day  1, 
including QTcF > 470 msec  in females and >  450 msec in  males  
d. Diabetes mellitus treated with insulin or hypoglycemic agents (including metformin ) 
or HbA1 C > 7% 
e. Asthma requiring hosp ital admission within the preceding 12 months  
f. Currently poorly controlled endocrine conditions, except for hypothyroidism that is 
stable (no treatment change in prior 6  months)  
g. Significant in fection or known systemic inflammatory process ongoing at Screen ing 
h. History of chronic or recurrent UTI, or UTI within 1  month prior to Screening  
7. History of malignancy within the preceding 3  years requiring treatment , with the 
exception of excised low grad e basal cell skin neoplasms .  
8. History of substance use disorder (SUD), including alcohol (AUD) or illicit drug use 
(excluding cannabis) within the preceding [ADDRESS_50666] by [CONTACT_47992]’s physician or health  care provider . 
10. Clinically significant illness within the 7 days prior to the administration of study 
intervention  
Prior/Concomitant Therapy  
11. History of multiple drug allergies or a history of allerg ic reaction to an 
oligonucleotide -based therapy  
12. Use of prescription medications (except for hormonal replacement/contraceptive 
medication for women  and inhaled medication for treatment of clinically stable asthma ) 
within 14 days or 5 half -lives  (whichever is longer)  prior to administration  of study 
intervention. Participants being treated for hypothyroid disease must be on stable 
treatment (no treatment changes in the preceding 6  months).  
13. Receipt of any v accin e (including COVID -19) within 14 days  prior to administration of 
study interventio n. 
14. Regular  use of OTC medications, including NSAID  (Periodic or occasional NSAID use 
to control temporary pain is not exclusionary.)  
Prior/Concurrent Clinical Study Experience  
15. Has received an investigational agent within 30 days or 5 half -lives  (whichever is longer) 
prior to dosing or is in follow -up of another clinical study prior to initial dosing with the 
study intervention . 
Diagnostic Assessments  
16. Seropositive for antibodies to HIV, HBV, or HCV at Screening (historical testing may be 
used if performed wi thin the 3 months prior to screening). NOTE: In participants with 
previous treatment for hepatitis C with direct -acting HCV medication and seroposit ivity 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50667] be undetecta ble (at least [ADDRESS_50668] 12 weeks apart), and 
the HCV infection must have been resolved or cured >  [ADDRESS_50669] results (AST, ALT, GGT, total bilirubin) above the normal range.  
19. Safety laboratory test result considered cl inically unacceptable for study participation by 
[CONTACT_737].  
Other Exclusions  
20. History of intolerance t o SC injection(s) or significant abdominal scarring that could 
potentially hinder study intervention administration or evaluation of local injection  site 
tolerability.  
21. Scheduled for an elective surgical procedure during the conduct of this study.  
22. Donation of > 500 mL of blood within the 2 months prior to administration of study 
intervention or donation of plasma within 7 days prior to Screening.  
5.3. Lifes tyle Considerations  
Caffeine , Alcohol , and Cannabis  
• During each dosing session, participant s will abstain fr om ingesting caffeine - or 
xanthine -containing products ( e.g., coffee, tea, cola drinks , and chocolate) for 12 hours 
before  the start of dosing until after collection o f the final PK and/or PD sample . 
• Study  participant s are to refrain from drinking  alcohol  and using cannabis from the 
screening visit until the final study visit and must have a negative breath  alcohol test on 
the day of the study visit prior to the EIA . 
Activity  
• Participants must not have  undertaken, or plan to undertake, a significant change in 
exercise levels from 48  hours prior to entrance into the clinical research center until the 
end of study.  
• Participants should a bstain from strenuous exercise for 48 hours before each blood 
collection for clinical laboratory tests. Participants may parti cipate in light recreational 
activities (e.g.,  walking at a pace <  3 miles per hour, shoppi[INVESTIGATOR_007], watering plant s) in that 
48-hour time period .  
Meals and Dietary Restrictions  
• Participants will be required to be fasted for at least 6 hours and then fed a stan dardized 
meal  in the clinic prior to administration of EtOH  on the day s of EIA s. 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 34 5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen  failure participant s to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory author ities. Minimal information includes demography, 
screen failure details, eligibility criteria, and  any SAE s. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. Participants may undergo rescreening on e time at the discretion of the Investigator or 
Sponsor. Only pregnancy test, hematology and chemistry, and coagulation studies may be 
repeated . Rescreened participant s should be assigned the same participant  number a s for the 
initial screening.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 35 6. STUDY INTE RVENTION  
Study intervention  is defined as an y investigational intervention (s), including placebo , intended 
to be administered to a study participant according to the study protocol.  
6.1. Study Intervention(s)  Administered  
DCR -AUD or placebo will be administered  subcutaneously as fixed doses .  
6.1.1.  Dose Levels and Dose Escalation  
Doses of DCR -AUD to be administered will ascend from 80  mg in Cohort  1, to 240  mg in 
Cohort 2, to 480  mg in Cohort 3, and 960  mg in the optional Cohort  4.  
Dose escalation refers to escalatio n to the next consecutive dose level in line with prespecified 
dose escalation  rules. For the purpose of this protocol, escalation rules are based on the emergent 
safety and PK profile s. 
Clinical doses are expressed in terms of the weight of the  DCR -AUD fr ee acid , rather than on 
that of the sodium salt  (Table  5).  
Table  5: Study Intervention Administered  
Arm Name  [CONTACT_48027] -AUD  Physiologic  saline  (0.9%  aqueous 
sodium chloride ) for injection  
Intervention Type  Drug  Drug  
Dose Formulation  solution for injection  n/a 
Unit Dose Strength  160 mg/mL  n/a 
Dose Level(s) and Frequency  80 mg, 240  mg, 480  mg, or 960  mg 
single dose  volume to match active  
single dose  
Route of Administration  SC injection (thigh or abdomen)  SC injection (thigh or abdomen)  
Use Experimental  Placebo comparator  
IMP or NIMP  IMP n/a 
Sourcing  Provided centrally by [CONTACT_47993] 
(Pharmacy staff i s not blinded)  
Packaging and Labeling  DCR -AUD  will be provided in vials. 
Each vial will be labeled as required 
per country.  n/a 
Abbreviations: IMP: investigational medicinal product;  n/a: not applicable; NIMP:  non-investigational medicinal 
product; SC: s ubcutaneous  
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 36 6.2. Preparation/Handling/Storage/Accountability  
6.2.1.  Handling and Accountability  
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and that any discrepan cies are 
reported and resolved before use of the study intervention.  
Only participant s enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention.  
The Investigator, institution, or the h ead of the medical institution (where applicable) is 
responsible for study interventi on accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for the final di sposition of unused study intervention are 
provided in the Pharmacy Manual.  
6.2.2.  Storage  
DCR-AUD is to be stored at or below 30 °C (inclusive) ; do not freeze.   
All study intervention must be stored in a secure, environmentally controlled and monitored 
(manual or  automated) area in accordance with the labeled storage conditions, with access 
limit ed to the Investigator and authorized site staff.  
The placebo comparator should be stored in accordance with the product labeling.  
6.2.3.  Preparation and Administration  
Study int ervention will be prepared by [CONTACT_8868]. A second 
medicall y qualified person must check the dose preparation prior to administration to be sure the 
correct dose has been prepared.  
If stored at 2 °C to 8°C, DCR -AUD  should be allowe d to warm to room temperature for 
approximately 1  hour before administration.  
DCR -AUD  is administered as a SC injection into the thigh or abdomen. The maximum volume 
of a single SC injection should not exceed 1.5 mL; if the dose requires an injection volum e 
> 1.5 mL, the total dose will be administered as 2 or more S C injections of equal volume  at 
separate injection sites in the abdomen . All used DCR -AUD vials will be retained and 
quarantined in the pharmacy . Once drug accountability is recorded to be accur ate, the vials will 
be destroyed on site per clinic SOP .  
Placebo will be administered as a n SC injection of physiologic saline (0.9%  aqueous sodium 
chloride ) in the thigh or abdomen at a volume equal to that of DCR -AUD .  
Complete details will be provided in the Pharmacy Manual.  
6.3. Measures to Minimize Bias: Randomizati on and Blinding  
This is a randomized, placebo -controlled, double -blind study , where the Investigator s, study site 
personnel  (excluding pharmacy staff) , CRO staff, sponsor Medical Monitor,  and study 
participants will be blinded  for the duration of the study . The Sponsor will remain unblinded for 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 37 the duration  of the study . This enables the Sponsor to immediate ly and comprehensive ly evaluate  
the safety of the study participants .  
Within each SAD cohort, the sentinel participants  will be randomly assigned to DCR -AUD or 
placebo in a 2:1 ratio.  The overall DCR -AUD to placebo ratio within each cohort is also 2:1. All 
participants will be centrally assigned to randomized study intervention using an Intera ctive 
Voice/Web Response System (IVRS/IWRS). Before the study is initiated, the telephone number 
and call -in directions for the IVRS and/or the log in information and directions for the IWRS will 
be provided to each site.  
Investigators , site staff  (excludi ng pharmacy staff) , CRO staff, sponsor Medical Monitor , and 
participants  will remain blinded to each participant’s assigned study intervention throughout the 
course of the study. To maintain this blind, the unblinded site pharmacy staff  will be responsible  
for the preparation and dispen sation of all study intervention.   
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to verify that randomization/dispensing has been done 
accurately.  
The IVRS/IWRS will be programmed with blind -breaking instructions. In case of an emergency, 
the Investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must  always be the first considerat ion in 
making such a determination. If the Investigator decides that unblinding is warranted, the 
Investigator should make every effort to contact [CONTACT_47994] a 
participant’s treatment assignment, unless this could delay emergen cy treatment of the 
participant. If a participant’s treatment assignment is unblinded, the Medical Monitor must be 
notified within [ADDRESS_50670] dose cohort. Modified dosing regimens 
may be explored if required based on emergent safety and tolerability  data or the occurrence of  
confirmed DLTs  (as defined in Section  7.3.1 ), and available PD or PK data, where applicable .  
At each decision point listed in Section  9.6, the SRC  will make a determination as whether to 
continue the dosing and enrollment as planned ; to interrupt dosing and enrollment in the current 
cohort or escalation to the next dose cohort; or to stop the study. However, if the SRC  decides 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 38 not to escalate the dose and a stop pi[INVESTIGATOR_47937], the SRC  may make a 
recom mendation to  (1) test  a lower dose than planned, (2) retest a previous dose, or (3) stop 
dosing.  The SRC may also elect to have an independent expert Data Safety Monitoring 
Committee (DSMC) convene if a s tudy stoppi[INVESTIGATOR_47938] a recommendation as 
to resumption , permanent discontinuation, or modification of the  trial that has been suspended or 
interrupted on the basis of an SRC decision (see Section  [IP_ADDRESS] ).  
6.6. Continued Access to Study Intervention  After the End of the  Study  
Not applicable.  
6.7. Concomitant Therapy  
All study p articipants must abstain from taking prescription drugs (except for hormonal 
replacement/contraceptive medication for women  and inhaled medication for treatment of 
clinically stable asthma ) within 14 days or 5 half -lives (whichever is longer) prior to 
admi nistration of study intervention until EOT. Participants being treated for hypo thyroid disease 
must be on stable treatment (no treatment changes in the preceding 6  months).  
Regular  use of OTC medicatio ns (including NSAIDs) is not allowed . Occasional use o f NSAID s 
for pain management is acceptable.  
Regular  use of vitamins is acceptable.  
Participants mu st not receive any vaccine in the 14 days prior to or following administration of 
study intervention.  
NOTE: Any medication (including OTC or prescription medi cines, vitamins, and/or herbal 
supplements) or vaccine that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:  
1. Reason for use  
2. Dates of admin istration , including start and end dates  
3. Dosage information , including dose and frequency  
6.7.1.  Rescue Medicine  
Rescue medication is permitted at the discretion of the Investigator .  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 39 7. DISCONTINUATION  OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION /WITHDRAWA L 
7.1. Participant Discontinuation/ Withdrawal from th e Study  
A participant  may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator  for safety, behavioral , compliance, or 
administrative  reasons .  
If a participant has a significant adverse reaction to alcohol at the Day  –1 visit ( before 
administration of DCR -AUD ), the participant  will be discontinued from the study . The 
participant  will be replaced.  
If possible, a t the time of discontinui ng from the study, an early termination (ET) visit should be 
conducted, as shown in the SoA  Table  1. 
If the participant  withdraws consent  for disclos ure of future information, the Sponsor  may retain 
and continue to u se any data collected before such a withdrawal of consent . 
If a participant  withdraws from the study, he/she may request destruction of any samples taken 
and not tested , and the Investigator  must document this in the site study records . 
The reason for part icipant discontinuation or withdrawal from the study will be recorded on th e 
eCRF. Participants who sign the ICF and are randomized but do not  receive the study 
intervention may be replaced. Participants who sign the ICF and are randomized and do receive 
the study intervention, and subsequently withdraw or are withdrawn or discon tinued from the 
study may be replaced at the discretion of the Sponsor.  
7.2. Lost to Follow up 
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The f ollowing actions must be taken if a participant  fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_47995] m issed visit as 
soon as possible and counsel the participant  on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant  wishes to and/or 
should continue in the study.  
• Before a  participant  is deemed lost to follow up,  the Investigator  or designee must 
make every effort to regain contact [CONTACT_6635]  (where possible, 3 telephone 
calls and , if necessary , a certified letter to the participant ’s last known mailing 
address or local equivalent methods). These contact  [CONTACT_14316] ’s medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 40 7.3. Cohort Stoppi[INVESTIGATOR_47939] a participant experiences a DLT  (Section  7.3.1 ), an SAE (Section  10.3.2 ), unless it is clearly 
the result of a non-study -related event, or a clinically relevant ECG finding as noted in 
Section  7.3.2 , enrollment and dosing of additional participants will be pau sed while the SRC 
reviews the event . Based on th is review, a decision will be made as to whether study enrollment 
and dosing may resume.  
Escalation to the next cohort will b e suspended if 2 or more participants in a cohort experience  
DLTs , until the SRC co nvenes to review the events and the totality of the safety data generated . 
Cohorts dosed at levels lower than the dose level at which the above criteria occurred may 
continu e dosing with the approval of the SRC . 
Dose e scalation will not be advanced  if exposure levels in humans exceed the mean AUC and 
Cmax values observed at the mid -dose level (100 mg /kg) in the 5 -week monkey toxicokinetic 
study (Study  Number 20 -A1203 -P-030; AUC 0-48h 383000 h r∙ng/mL and C max [ZIP_CODE] ng/mL ). 
All ongoing participants wil l continue to be followed for safety assessments as indicated in the 
schedule of activities.  
The Sponsor will promptly notify all sites if cohort stoppi[INVESTIGATOR_47940].  
7.3.1.  Dose Limiting Toxicities  
A DLT is defined  as:  
• an AE o f ≥ Grade 3 intensity (CTCAE Version 5.0 ) in one participant , unless it is clearly 
the result of a non -study -related event  OR 
• any 2 AEs of ≥ Grade 2 intensity in the same body system  in one participant . 
7.3.2.  Electrocardiogram Findings  
If a clinically significant f inding is identified (including, but not limited to , the QTcF findings 
below ) after enrollment, the Investigator or qualified designee will determine if the participant 
can continue in the study and if a ny change in participant management is needed. This r eview of 
the ECG printed at the time of collection must be documented. Any new clinically relevant 
finding should be reported as an AE.  
• Absolute QTc F > 500 msec and/or  
• QTcF change of >  60 msec from base line 
7.4. Study Stoppi[INVESTIGATOR_47941] : 
• 2 participants develop a Grade 3 CTCAE  event  unless it is clearly the result of a 
non-study -relate d event . 
• 1 participant deve lops a ≥ Grade 4 CTCAE event  unless  it is clearly the result of a 
non-study -related event . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50671] that an  external,  independent  and unblinded DSM C be 
convene d to review th e decision  and make a recommendation  to the SRC  as to whether the study 
should stop or continue with no changes or continue with appropriate modification s to address 
the safety concern  (see Section  [IP_ADDRESS] ). Should the DSMC recommend stoppi[INVESTIGATOR_10098] , all 
ongoing participants will continue to be followed for safety assessments as indicated in the 
schedule of activities.  
The Sponsor will promptly notify the site if study stoppi[INVESTIGATOR_47942].  
8. STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the SoA  (Section  1.3). Protocol  waiver s or 
exemptions are not allowed . Participants may undergo rescreening one tim e at the discretion of 
the Investigator or Sponsor. Only pregnancy test, hematology and chemistry, and coagulation 
tests may be repeated . 
Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence 
or awareness.  
Adherence to the study design requirements, including those specified in  Table  1 and Table  3 
(Section  1.3), is essential and required for study c onduct.  Participants will be given a diary to 
track AEs and temperance for the study duration. Participant s will be trained on the use of the 
diary prior to discharge from the clinic for Visit [ADDRESS_50672] reasons for scr eening failure, as 
applicable.  
If multiple assessments are due, the order of priority should be ECG, vital s, PK, and then other 
assessments . 
The maximum amount of blood drawn from each participant at any visit (including efficacy, PK, 
biomarker, and safety  laboratory testing) will not exceed:  
• Per Visit :  
− 30 mL for Sentinel group  
− 56 mL for Expanded group  
• Per 8 -week period:  
− 156 mL for Sentinel group  
− 297 mL for Expanded group  
Repeat or unscheduled samples may be taken for safety reasons or for technical issu es with the 
samples.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 42 8.1. Efficacy Assessments   
This is a Phase  1 study with the primary objective of evaluating safety. Pharm acokinetic  and 
PD assessments are detailed in Sections  8.5 and 8.7, respectively .  
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). Safety 
assessments will be conducted in all participants  at every study v isit unless otherwise specified.  
Site personnel will be provided training in the use of all study -specific instruments (see the Study 
Reference M anual).  
8.2.1.  Physical Examination s 
Complete physical examinations will be conducted at every  visit.  
Physical examin ation s will include, at a minimum, assessments of the Cardiovascular, 
Respi[INVESTIGATOR_696], Gastrointestinal , Neurological , and S kin systems. Height will also be measured and 
recorded  at Day 1 and weight  will be measured and recorded at every visit . 
• Investigator s should pay special attention to clinical signs related to previous serious 
illnesses  or AEs . 
• All physical examinations should include inspection of the injection site.  
8.2.2.  Vital Signs  
Temperature  (by [CONTACT_47996]) , pulse rate, respi[INVESTIGATOR_697], and blood pre ssure will be assessed.  
Blood pressure and pulse measurements will be assessed in the seated  position  with a completely 
automated device. Heart rate will be measured using telemetry during EIAs. Manual techniques 
will be used only if an automated device is  not available.  Blood pressure and pulse 
measurements should be preceded by [CONTACT_2669] [ADDRESS_50673] for the participant in a quiet 
setting without distractions ( e.g., television, cell phones).  
Temperature will be obtained in degrees Celsius (°C), pulse rate will be counted for a full minute 
and recorded in beats per minute, and respi[INVESTIGATOR_47943] a full minute and recorded 
in breaths per minute.  
Note:  In addition to standard vital sign measurements  for safety , vital signs will be recorded as 
part of the EIA  and results will be identified as such (e.g., HR for EIA ) in the eCRF.  
8.2.3.  Electrocardiograms  
Standard 12 -lead ECGs will be performed in the supi[INVESTIGATOR_47944] 10 minutes. ECGs will be obtained u sing an ECG machine that automatically 
calculates the heart rate and measures PR, QRS, QT, and corrected QT interval (QTcF, Fridericia 
correction). Refer to  Section  7.3.2  for QTc withdrawal criteria and any addit ional readings that 
may be necessary.  
The Investigator or designee is responsible for reviewing the ECG(s) to assess whether the 
results are within normal limits and to determine the  clinical significance of the results. These 
assessments will be recorded on the CRF . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 43 Note: If multiple assessments  are due , the order of priority should be ECG, vitals, PK, and then 
other assessments, with the PK sampling being performed preferably at the  nominal time point . 
ECGs also will be conducted for EIA assessments . Thes e ECG  result s will be recorded as part of 
the EIA and will be identified as such (e.g., ECG  for EIA) in the eCRF.  
8.2.4.  Alcohol Consumption  via Timeline Follow Back   
Study participants are to refrain from drinking alcohol throughout the outpatient portion of the  
study  (sentinel participants will refrain from alcohol throughout the in -clinic  portion as well) . At 
every visit, the TLFB will be used to assess each participant ’s abstention  from alcohol since the 
previous visit. The TLFB was developed as a procedure to  aid recall of past drinking ( Sobell & 
Sobell, 1992 ). Currently, self -reports are the only viable method for retrospectively measuring 
drinking with any precision. Alternative methods exist, but they are either impracti cal 
(e.g., continuous direct observation), fraught with problems (e.g., alcohol sweat patches) or they 
only measure very recent drinking (e.g., biochemical indicators or blood alcohol tests). 
Consequently, there is no practical alternative technology other  than self-reports for 
retrospectively assessing drinking. TLFB stands as the most exhaustively evaluated method that 
can be used for this purpose.  
8.2.5.  Columbia -Suicide Severity Rating Scale  
The C -SSRS is a suicidal ideation rating scale created by [CONTACT_47997] 
(Posner  et al.,  2011 ). It rates an individual's degree of suicidal ideation on a scale, ranging from 
"wish to be dead" to "active suicidal ideation with specific plan and intent."  
The scale identif ies be haviors that may be indicative of an individual's intent to commit suicide. 
The C -SSRS is used extensively across primary care, clinical practice, surveillance, research, and 
institutional settings  and is part of a national and international public h ealth initiative involving 
the assessment of suicidal ideation and behavior.  The C -SSRS requires no mental health training 
to administer it. The C SSRS w ill be  administered by [CONTACT_3784], trained raters.  
The Baseline  version will be  administered at Screenin g and at subsequent visits the “C-SSRS 
Since Last Visit ” version will be  administered.  
8.2.6.  Mini -International Neuropsychiatric Interview  
The MINI  is a brief structured  diagnostic interview to meet the need for a short but accurate 
structured psychiatric interv iew for multicenter clinical trials  (Sheehan  et al., 1998 ). This 
validated tool can be administered in a short period of time  (approximately 15 minutes ) and will 
be administered at screening  to exclude participants with  major psychiatric disorder s. The MINI 
will be  administered by a Health Care Provider . 
8.2.7.  Clinical Safety Laboratory Assessments  
See Section  10.[ADDRESS_50674] of clinical laboratory tests to be performed and the SoA s 
(Section  1.3) for the timing and frequency.  
The Investigator  must review the laboratory report, document this review  in the eCRF , and 
record any clinically relevant changes occurring during the study in the AE s ection of the eCRF. 
The laboratory reports must be filed with the source documents.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 44 All laboratory tests with values considered clinically significantly abnormal during parti cipation 
in the study should be repeated (central laboratory) until the values ret urn to normal or stabilize 
at a level no longer considered clinically significant by [CONTACT_47998].  
• If such values do not return to normal/baseline with in a period of time judged 
reasonable by [CONTACT_737] , the etiology should be identified and the Sponsor  
notified.  
• All protocol -required laboratory assessments, as defined in Section  10.2, must be 
conducted in accordance with the Laboratory Manual and the SoA  (Section  1.3).  
• If laboratory valu es from non -protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_737]  (e.g., SAE or AE), then the results 
must be recorded in the eCRF.  
8.3. Adverse Events , Serious Adverse Events , and Other Safety 
Reporting  
The definitions of AE s, SAE s, and adverse events of special interest ( AESI ) can be found in 
Section s 10.3.[ADDRESS_50675] follow -up 
visit (including CFU, if applicable) at the time  points specified in the SoAs (Section  1.3). 
Ongoing SAEs will be followed unt il resolution.  
Medical occurrences that begin before the start of study intervention  but after obtaining informed 
consent will be recorded on the Medical History/Current Medical Conditions section of the 
eCRF , not the AE s ection . 
All SAE s will be recorded and reported to the Sponsor  or designee within  24 hours, as indicated 
in Section  10.3.5 . The Investigator  will submit any updated SAE data to the Sponsor  within 
24 hours of it being available.  
Investigator s are no t obligated to actively seek AE  or SAE after conclusion of study 
participa tion. However, if the Investigator  learns of any SAE, including a death, at any time after 
a participant  has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention  or study participation, the Investigator  must promptly notify the 
Sponsor . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 45 8.3.2.  Method of Detecting AE s and SAE s 
Care will be taken not to int roduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.3.3.  Follow -up of AE s and SAE s 
After the initial AE/SAE report, the Investigator  is required to  proactively follow each 
participant at subsequent visits/contacts. All SAEs and AESI s (as defined in  Section  10.3.3 ), will 
be followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow -up (as defined in Section  7.2). Further information on follow -up procedures is 
provided  in Section  10.3.4. 
8.3.4.  Regulatory Reporting Requirements for SAE s 
Prompt notification by [CONTACT_47999] s and the safety of a study 
intervention  under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory author ity and other 
regulatory agencies about the safety of a study intervention  under clinical investigation.  The 
Sponsor  will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs/IEC s, and Investig ators. 
Investigator  safety reports must be prepared for suspected unexpected serious adverse reactions  
(S[LOCATION_003]R)  according to local regulatory r equirements and Sponsor  policy and forwarded to 
Investigator s as necessary.  
8.3.5.  Pregnancy  
Details of all pregnancies i n female participants and female partners of male participants will be 
collected after the start of study intervention and until  [ADDRESS_50676] dose . 
If a pregnancy is reported, the Investigator  should inform the Sponsor  within 24 hours  of 
learnin g of the pregnancy and should follow the procedures outlined in Section  10.4.4 . 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for me dical reas ons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
The participant or pregnant partner  will be followed to determin e the outc ome of the pregnancy. 
The Investigator will collect follow -up information on the participant or pregnant partner  and the 
neonate , and the information will be forwarded to the Sponsor . 
Any post -study pregnancy -related SAE considered reasonably rel ated to th e study intervention 
by [CONTACT_48000]  8.3.4 . While the 
Investigator  is not obligated to actively seek this information in former study participa nts, he or 
she may learn of an SAE through spontaneous reporting.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 46 8.4. Treatment of Overdose  
For this study, any dose  of DCR -AUD greater than  the specified dose w ill be considered an 
overdose.  
Dicerna  does not recommend specific treatment for an overdose.  
In the event of an overdose, the Investigator shou ld: 
• Contact [CONTACT_9306] . 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
DCR -AUD PD effects  can no longer be detected.  
• Document the quantity of the exces s dose.  
8.5. Pharmacokinetics  
Blood samples will be collected for measurement of plasma concentrations of AUD and/or its 
metabolites as specified in the SoAs (see Section  1.3). Urine samples will be collected for 
meas urement of urine co ncentrations of AUD and/or its metabolites as specified in the SoA 
(Section  1.3).  
Instructions for the collection and handling of biological samples will be provided by [CONTACT_48001] e Laboratory Specification document. The actual date 
and time (24 -hour clock time) of each sample will be recorded.  
Each plasma sample will be divided into 2 aliquots (one for PK and one backup). Samples 
collected for analyses of plasma concentrations of A UD and/or its metabolites may also be used 
to evaluate safety or efficacy aspects related to concerns arising during or after the study.  
Pharmacokinetic parameters to be determined may include clearance (CL) and apparent volume 
of distri bution (Vd/F) estim ates, along with secondary parameters of area under the 
concentration curve (AUC), maximum observed concentration (C max), minimum observed 
concentration (C min), time to maximum concentration (T max), and terminal elimination half -life 
(t1/2). Additional par ameters may be estimated if deemed appropriate.  
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by [CONTACT_48002] b ut will not constitute a protocol amendment. The IRB/IEC will be informed 
of any safety issues that require alteration of the safety monitoring scheme or amendment of 
the ICF. 
Drug concentration information that may  unblind the study wil l not be reported t o investigative 
sites or blinded personnel until the study has been unblinded.  
8.6. Genetics  
A sample of whole blood  for DNA isolation will be collected from participants who have 
consented to participate in the optional genetic analysis comp onent of the study. Participation is 
optional ; participants who do not wish to participate in the genetic research may still participate 
in the study.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 47 In the event of DNA extraction failure, a replacement genetic blood sample may be requested 
from the part icipant. Sign ed informed consent will be required to obtain a replacement sample , 
unless it was included in the original consent.  
See Section  10.5 for information  regarding genetic research. Details on processes for collection 
and shipment and destruction of these samples can be found in the Laboratory Manual . 
8.7. Pharmacodynamic s 
DCR -AUD is designed to selectively reduce ALDH2 activity in the liver and the conversion of 
acetaldehyde to acetic acid. The build -up of  acetaldehyde causes unpleasant effects after 
drinking (e.g., headache, facial flushing, tachycardia , nausea , vomiting ). As such , the PD activity  
of DCR -AUD will be assessed during EIAs using blood biomarkers  (alcohol, acetaldehyde, and 
acetate ) and objective  physiological biomarker s (heart rate and facial skin temperature) . 
Participants ’ subjective experience of the effects of alcohol will be assessed using the  SEAS . 
Instructions for the collection and handling of biological samples will be provided by [CONTACT_48003]  
8.7.1.  Ethanol Interaction Assessments  
Serial EIAs will be performed in designated participants to assess the indirect PD effects  of 
ALDH2  reduction  (acetaldehyde increase), including  plasma  acetaldehyde , acetate , and ethanol, 
heart rate , facial skin temperature , and s ubjective feelings of alcohol intoxication or intolerance 
using the SEAS (Morean et al., 2013 ). Adverse events , vital signs , and ECG  will also  be 
monitored and recorded  for safety . Assessments  will be measured for up to 2 .5 hours following 
ethanol administration. Published literature consistently demonstrate that administration of 
low/moderate alcohol intake (0.1 -0.8 g/kg) in human  ALDH2  mutatio n homo - or heterozygotes  
results in clearly differentiated  and statistically si gnificant increases in blood acetaldehyde, heart 
rate, and facial skin temperature compared with ALDH2  normal alleotypic controls (Bae et al., 
2012; Peng  et al., 1999 ; Peng et al., 2007 ; Nishimura et al., 2002 ; Enomoto  et al., 1991 ). 
EIAs will be conducted in accordance with the SoA in Section  1.3. Should an EIA be missed , 
due to COVID -[ADDRESS_50677] 6  hours prior to administration of a standardized mea l and then 
ethyl alcohol ( EtOH ) and must have a negative breath  alcohol test on the day of the study visit 
prior to the EIA. Prio r to each EIA, venous  catheter s will be placed at least  [ADDRESS_50678] EIA vital signs are assessed  at time 0 . During the EIA , participants will receiv e nothing by 
[CONTACT_1966] ( remain NPO ) except w ater ad libitum . 
Participants  will consume a fixed d ose of ethanol  mixed in a liquid that has no additional 
alcohol , no caffeine, and is low in sugar . The ethanol dose will be  0.4 g/kg ethanol  for male 
participants and 0.34  g/kg ethanol  for female participants , not to exceed 28  grams EtOH for men 
or 24  g EtOH for women per EIA . Ethanol will be consumed in 4 aliquots over a 30 -minute 
period . Assessments will be made over an estimated 2 .5-hour period , as detailed in Table  3. 
Participants will remain in the Phase 1 teleme try unit for an  overnight admission. The 
Investigator will not discharge any participant experiencing ongoing effects of ethanol 
administration u ntil it is deemed medically safe to do so.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 48 [IP_ADDRESS].  PD Biomarkers for EIA  
[IP_ADDRESS].1.  EIA Blood Biomarker s 
Blood b iomarkers to be as sessed include measurement of acetaldehyde , acetate , and ethanol . 
Blood samples (maximum 32 mL/day)  will be collected via a  venous access device immediately 
prior to EtOH consumption  (time 0) and at 15, 30, 45, 60, 90, 120, and 1 50 minutes postdose  
(Table  3). Additional detai ls regarding b lood sample collection and processing will be detailed in 
the Laboratory Manual . 
[IP_ADDRESS].2.  EIA Physiologica l Biomarkers  
EIA assessments will include measurement of heart rate and facial skin temperature . Facial skin 
temperature will be measured using a surface scanning thermometer . Heart rate  will be 
monitored by [CONTACT_48004].  Site personnel will be provided training in the use of all 
study -specific instruments (see the Study Refer ence M anual ). 
Heart rate , using telemetry , and facial skin temperature will be collected immediately predose 
(time 0) and at 15, 30, 45, 60, 90, 120 , and 150  minutes postdose.  
[IP_ADDRESS].3.  EIA Subjective Effects of Alcohol Scale  
For each EIA, participants will complete  the SEAS predose (during the Rest Period ) and at 
30, 60, 90, 120, and 1 50 minutes postdos e. The SEAS is a 14 -item tool that allows participants  to 
rate the subjective effects of alcohol described  in Table  6. Partici pants  will rate the extent to 
which they are feeling each of the effects in the present time.  
Table  6: Subjective Effects of Alcohol Scale (SEAS)  
Feeling  Not at All  Moderately  Extremely  
Relaxed  0 1 2 3 4 5 6 7 8 9 10 
Wobbly  0 1 2 3 4 5 6 7 8 9 10 
Lively  0 1 2 3 4 5 6 7 8 9 10 
Secure  0 1 2 3 4 5 6 7 8 9 10 
Rude  0 1 2 3 4 5 6 7 8 9 10 
Woozy  0 1 2 3 4 5 6 7 8 9 10 
Fun 0 1 2 3 4 5 6 7 8 9 10 
Calm  0 1 2 3 4 5 6 7 8 9 10 
Aggressive  0 1 2 3 4 5 6 7 8 9 10 
Dizzy  0 1 2 3 4 5 6 7 8 9 10 
Demanding  0 1 2 3 4 5 6 7 8 9 10 
Mellow  0 1 2 3 4 5 6 7 8 9 10 
Funny  0 1 2 3 4 5 6 7 8 9 10 
Talkative  0 1 2 3 4 5 6 7 8 9 10 
Source: Morean et al. 2013 . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 49 [IP_ADDRESS].  Stoppi[INVESTIGATOR_47945] o f an EIA, administration of alcohol to a participant may be stopped for the 
following physiologic responses , though follow -up EIA assessments will be conducted :  
• Any vomiting or severe nausea (as judged by [CONTACT_10670])  
• Systolic blood pressure increase of  > 25 mmHg (and/or to a level >  150 mmHg ) or 
decrease of >  10 mmHg (to systolic <  90 mmHg ) 
• Diastolic  blood pressure  decrease to <  50 mmHg  or any decline accompanied by 
[CONTACT_48005] (pre -syncope, syncope , lightheadedness ) 
• HR increase of >  20 beats  per minute  (or to a level >  100 beats per minute)  
• Temperature increase of >  1°Ce lsius  
• Any clinically meaningful change in affect or clinical status, per Investigator or 
supervising designee ’s clinical judgment.  
[IP_ADDRESS].  Follow -up of Participants Who Continue to Have Positive Ethanol Reaction 
Symptoms at Day [ADDRESS_50679] positive ethanol  reaction symptoms at the Day 169 EIA (e.g., nausea, 
vomiting, or substantial flushing) will return every 28 (±7) days for follow -up EIAs until the 
positive ethanol re action symptoms abate. These CFU  EIAs will not require overnight admission 
to the clinic , but a ll other aspects of the EIA will be conducted  (see Table  3). Participants will be 
observed for no less than 6 hours after  ethanol administration an d will not be discharged until the 
Investigator deems it medically safe to do so .  
8.8. Immunogenicity Assessments  
Antibodies to DCR -AUD  will be evaluated in serum  samples collected from all participants 
according to the SoA. Additiona lly, serum  samples should also be collected at the final visit from 
participants who discontinued study intervention or were withdrawn from the study. These 
samples will be tested by t he Sponsor  or Sponsor 's designee.  
Serum samples will be screened for ant ibodies binding to DCR -AUD , and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to DCR -AUD  and/or furthe r characterize the immunogenicity of DCR -AUD . 
The detection and characte rization of antibodies to DCR -AUD  will be performed using a 
validated assay method by [CONTACT_23788] . All samples collected for 
detection of antibodies to DCR -AUD  will also be evaluated for DCR -AUD  serum concentration 
to enable int erpretation of the antibody data. Antibodies may be further characterized and/or 
evaluated for their ability to neutralize the activity of the study intervention(s).  Samples for the 
detection and characterization of antibodies to DCR -AUD will be stored unt il a validated assay 
method is available .  
8.9. Health Economics  
Health Economics  parameters are not planned  in this study . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 50 9. STATISTICAL CONSIDERATIONS  
9.1. Statistical Hypotheses  
Statistics will  be descriptive. No tests of statistical inference are planned.  
9.2. Sample S ize Determination  
No formal sample size estimations were performed. The following s ample sizes were considered 
sufficient to provide an initial assessment of the safety profile of DCR -AUD  in HVs, and 
adequate for the purpose of  describing PK/PD data in HV s.  
• 27 HV participants (3 cohorts with 9 participants each, 2 to 1 randomization) , plus an 
additional 9 HV participant s (2 to 1 randomization) , for a total of 36, if an optional 
fourth  cohort is enrolled . 
The sample size is based on clinical rather than sta tistical considerations.  
9.3. Populations for Analyses  
For purposes of analysis, the following populations are defined:  
Population  Description  
Enrolled  All participants who sign the ICF.  
Randomized  All participants who sign the ICF and who are randomly assig ned to study 
intervention.  
Pharmacokinetic  All participants randomly assigned to study intervention and who receive  a 
full dose of DCR -AUD and have sufficient data for at least [ADDRESS_50680] 1  postdose 
PD assessment . 
Safety  All participants randomly assigned to study intervention and who receive  a 
full dose of study intervention . Participants will be analyzed according to 
dose received.  
 
9.4. Statistical Analyses  
9.4.1.  General Considerations  
In general, summary statistics (n, mean, SD, median, minimum, and maximum for continuous 
variables, and num ber and percentage of participants  in each categ ory for categorical variables) 
will be provided for all variables.  
Baseline is defined as the last non -missing measurement prior to the date and time of the dose of 
study intervention . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50681] data listings.  
9.4.2.  Primary  Endpoint(s)  
The primary endpoint for all parts of the study is assessment of the i ncidence and severity of 
AEs, SAE s, and DLT s. 
All safety analyses will be performed on the Safety Population. Adverse events will  be defined 
as treatment -emergent AEs if they have a start date on or  after the administration of study 
intervention  during the treatment period . Frequency and percentages will be used to summarize 
AEs, SAEs, AEs of special interest, and AEs by [CONTACT_3773] p. Laboratory values will be reported 
by [CONTACT_48006], if applicable.  
By-subject listings will be provided for deaths, SAEs,  and DLTs.  
9.4.3.  Secondary  Endpoint (s) 
Pharmacokinetic analyses will be performed on Pharmacokinetic Population. Actual samp ling 
times will be used for all parameter estimations.  
Plasma concen trations and PK parameters will be listed and summarized by [CONTACT_48007]. The arithmetic mean, SD, CV %, geometric mean, geometric 
CV%, minimum, medi an, and maximum will be presented.  
Descriptive statistics and change  from baseline will be provided for PD assessments , including 
acetaldehyde accumulation (absolute values and AUC) during the EIAs , where applicable.  
Additional PK parameters may be estima ted if deemed appropriate. Details will be provided in 
the PK Analysis Plan. Analysis of PK parameters may be reported in a supplement to the CSR.  
PK analyses will be conducted with noncompartmental and/or compartmental models to 
determine PK parameter est imates . Population PK and Population PK -PD analyses may be 
performed and will be reported in a separate report.  
9.4.4.  Exploratory Endpoint(s)  
Exploratory analyses will be conducted as deemed appropriate and will be detailed in the SAP.  
9.4.5.  Other Safety Analyses  
Desc riptive statistics and change from baseline will be provided for clinical laboratory 
parameters , vital sign  parameters , exploratory biomarkers, and [ADDRESS_50682] -baseline values will be presented. 
Mean laboratory values over time will be plotted by [CONTACT_7169].  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 52 9.5. Interim Analyses  
One or more interim analyses (IA) may be conducted  by [CONTACT_48008]  a possible 
safety or PD signal in the emerging blinded data . The timing of any IA will be dictated by [CONTACT_48009]. The Sponsor  may elect not to perform an IA if the 
emerging data do not warrant its conduct . 
As part of any IA, all study site personnel will remain bl inded, but certain members of the 
Sponsor staff will be unblinded  to randomization for the duration of the study . Complete 
information regarding unblinding of the Sponsor will be detailed in the Study Blinding Plan.  
The SAP will describe the conduct of an IA in greater detail  if warranted. 
9.6. Safety Review  Committee  
An SRC will conduct periodic  reviews and will review all cumulative safety, tolerability, and 
available PD data on participants acro ss all cohorts, approximately every [ADDRESS_50683] to cohort expansion, dose escalation , and the possible 
occurrence of DLTs  and study stoppi[INVESTIGATOR_004]  (see Section  7.4).  
At its discretion, and based on clinical judgment, the SRC may suspend dosing of the study at 
any time , even for reasons not explicitly stated elsewhere , and refer to the DS MC for any 
potential concern regarding  participant safety or wellbeing . In addition, t he DSMC will be 
convened on an ad hoc basis if an AE triggers stoppi[INVESTIGATOR_004]. The DSMC will review data and 
advise on whether the study should be stopped to ensure the safety of study participants. 
Complete d etails on the responsibilities of the DSMC are provided in the SRC  charter.   
As noted in  Section  6.1.1 , progression from one cohort to the next higher dose is contingent upon 
SRC review.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 53 Table  7: Minimal Timing of the Safety Review Committee Data Reviews  
Review of sentinel  dose 
group  for continuation 
of dosing within a 
cohort  The SRC must review the  available  safety data (as specified in the SRC charter) 
collected on the first 3 participants ( “sentinel group ”) dosed in each cohort 
(randomized 2:1; DCR -AUD: placebo), through  at least the Day  [ADDRESS_50684] review the available safety data collected on all 9 participants dosed 
in a given cohort (through at least the Day  15 assessments including Day  15 EIA 
data for applicable  participants) before dose escalation to the next cohort can occur. 
In addition, the SRC must review 72 -hr PK data on all participants in  a given cohort 
before dose escalation , to ensure that exposure levels do not exceed those observed 
at the mid -dose in the 5 -week mo nkey toxicokinetic study  
(AUC 0-48h 383000  hr•ng/mL and C max [ZIP_CODE] ng/mL ). 
The data to be revie wed will be specified in the SRC charter.  
Occurrence of a DLT  Upon the occurrence of a DLT (see  Section  7.3.1 ), all dosing and enrollment into 
the current cohort or escalatio n to the next cohort will be interrup ted until safety 
data can be reviewed by [CONTACT_12217]. The SRC will review  the events associated with 
the DLT as well as  the cumulative safety data collected on all participants 
previously dosed. The SRC will determine wheth er dosing, enrollment , and/or dose 
escalation may resume.  
Occurrence of a safety 
issue that , in the SRC ’s 
clinical judgment , could 
affect participant  safety 
or study conduct  Upon the occurrence of a situation or safety question that could affect participant  
safety  or study conduct,  the SRC will meet to discuss the issue . Actions to be taken 
includ e, but are not limited to:  
• Discontinuation of an individual participant  
• Discontinuation  of dosing at a certain dose level  
• Referral to the DSMC for review and recommen dation , should  a pattern of 
AEs of concern  be identified , regardless of severity  
Occurrence of a 
potential study stoppi[INVESTIGATOR_47946] a potential study stoppi[INVESTIGATOR_1877]  (see Section  7.4), all dosing 
and enrollment will be interrupt ed until safety data can be reviewed by [CONTACT_12217]. 
The SRC will review  the ev ents associated with the triggering of the stoppi[INVESTIGATOR_47947]. 
The SRC will determine whether dosing,  enrollment , and/or dose escalation may 
resume.  The SRC may elect to refer the issue that triggered the study interruption to 
the DSM C for an independent review and recommendation regarding  study 
resumption.   
Abbreviations: AE: adverse event; AUD: alcohol  use disorder; DLT; dose -limiting toxicity; DSMC: Data Safety Monitoring 
Committee; EIA: ethanol interaction assessment; SRC: Safety Review Committee  
For additional details on the composition of the SRC  and DSMC , refer to Section  10.1.5 . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 54 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Regulatory, Ethical, and Study Oversight Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the follo wing:  
• Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and Council for International Organizations of Med ical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice ( GCP) Guidelines  
• Applicable laws and regulations  
The protocol, protocol amendments, ICF, Investigator  Brochure, and other relevant documents 
(e.g., advertisements)  must be submitted to an IRB/IEC by [CONTACT_46378]/IEC before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for  changes necessary to eliminate an immediate 
hazard to study participants.  
The Investigator  will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the req uirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs o r other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of  21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if ap plicable), and all other applicable local regulations  
10.1.2.  Financial Disclosure  
Investigator s and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financ ial 
certification or disclosure statements to the appropriate regulatory authorities. Investigator s are 
responsible for providing information on financial interes ts during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Conse nt Process  
Each interested prospective participant (or legally authorized representative) will receive an 
informed consent document that contains study informatio n and be given ample time to read the 
information and consider participation. The Investigator  or his/her representative will explain the 
nature of the study and its risks and potential benefits to the prospective participant or his/her 
legally authorized representative and answer all questions regarding the study.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50685] (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center. Adolescents (12 to <  18 years of age, or older than 12  years but 
younger than the age of maj ority according to local regulations) must be able to provide written 
assent for participation. For  children younger than [ADDRESS_50686] current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the parti cipant or the participant’s legally authorized 
representative.  
10.1.4.  Data Protection  
Participants will be assigned a unique identifier by [CONTACT_1034] . Any participant records or 
datasets that are transferred to the Sponsor  will contain the identifier only; part icipant names or 
any information which would make the participant identifiable will not be transferred.  
The participant must be informed that h is/her personal study -related data will be used by [CONTACT_48010]. The  level of disclosure must also be 
explained to the participant s, who will be required to give consent for their data to be used as 
described in the informed consent   
The participant must be informed that his/her medical records may be examined by [CONTACT_19491] , by 
[CONTACT_6667]/IEC members, and by [CONTACT_48011].  
10.1.5.  Committees Structure  
[IP_ADDRESS].  Safety Review  Committee  
The SRC  will comprise the PI [INVESTIGATOR_1238]/or subinvestigat or, the Sponsor Medical Monitor , and the 
CRO Medical Monitor .  
See Section  9.6 for further  details regarding the SRC.  
[IP_ADDRESS].  Data Safety Monitoring  Committee  
The independent DSMC will comprise appropriately qualified clinicians who are not involved in 
the study. The DSMC will provide a comprehensive review of study safety and tolerability data . 
Further operational details will be prespecified in the DSMC charter . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50687] o nce a 
year, and tabular study summary  results will be posted to www.ClinicalTrials.gov  within 1 year 
of study completion . 
10.1.7.  Data Quality Assurance  
All participant data relating to the study w ill be recorded on pr inted or electronic CRF  (eCRF) , 
unless transmitted to the Sponsor  or designee electronically ( e.g., laboratory data). The 
Investigator  is responsible for verifying that data entries are accurate and correct by [CONTACT_48012].  
The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections an d provide direct acce ss to source data documents.  
Monitoring details describing strategy (e .g., risk -based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibili ties, and requirement s, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in the Monitoring Plan . 
The Sponsor  or designee is responsible for the data management of this study , includi ng quality 
checking o f the data.  
The Sponsor  assumes accountability for actions delegated to other individuals (e .g., CROs ). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_1191], compl ete, and verifiable from source 
documents; that the safety and rights of participants are being protected ; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_14344] 5 years after study completion unless local regulations or 
institutional policies require a longer rete ntion period. No records m ay be destroyed during the 
retention period without the written approval of the Sponsor . No records may be transferred to 
another location or party without written notification to the Sponsor .  
10.1.8.  Source Documents  
Source documents pr ovide evidence for the exi stence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the Investigator ’s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the  
source documents , or the discrepancies must be explained. The Investigator  may need to request 
previous medical records or transfer records, depending on the study. Also, current medical 
records must be available.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50688] been collected and a study -site closure vi sit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.   
Reasons for the early closure of a study site by [CONTACT_14345]:  
• Investigator noncompliance with the protocol, GCP, or regulatory requirements  
• Unsatisfactory enrollment with respect to quantity or quality  
• Incomplete data collection; inaccurate or knowingly false data su bmission  
• The PI [INVESTIGATOR_47948], and no replacement can 
be found.  
• The SRC  determines that termination of the study is in the best interest of the 
research participants.  
• The Sponsor, Investigator or IRB/IEC determines that continua tion of the study will 
not serve any scientific purpose.  
• Circumstances beyond the control of the Sponsor or Investigator make it 
unreasonable to require the study's continuation.  
• A request to discontinue the study by a regulatory or health aut hority . 
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigator s, the IECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the 
reason for termination or suspension, as specified by [CONTACT_941] a pplicable reg ulatory requirements. The 
Investigator  shall promptly inform the participant s and should assure appropriate participant  
therapy and/or follow -up.  
The complete set of stoppi[INVESTIGATOR_47949]  7. 
10.1.10.  Publication Policy  
Publication of a summary of the results of the study is permissible according to the Sponsor and 
is not inconsistent with the preceding affirmation. Scientific dissemination of the results of this 
study is encouraged. Any formal  publication of data collected as a result of the study will be 
considered a joint publication by [CONTACT_48013], Inc. or their designees. Authors hip will be determined by [CONTACT_48014] l ine with International Committee of Medical Journal Editors authorship requirements.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50689].  
Note: Any language relating to these issues appearing in the clinical study  agreement will 
supersede that which is outlined in this section . 
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50690] document their review of each laboratory safety report.  
Laboratory/analyte results  that could unblind the s tudy will not be reported to investigative sites 
or other blinded personnel until the study ha s been unblinded . 
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 60 Table  8: Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Red blood cell count  
 hemoglobin  
 hematocrit  
 reticulocytes  
 platelet count  
Only at Days -1, 4, 2 9, 85, and 169  
 mean corpuscular volume (MCV)  
 mean corpuscular hemoglobin (MCH)  
 mean corpuscular hemoglobin  
concentration (MCHC)  White blood cell count  
 
 
 
 
Only at Days  -1, 4, 29, 85, and 169  
 lymphocytes, abs and %  
 monocytes, abs and %  
 eosinophils, a bs and %  
 neutrophils, abs and %  
 basophils, abs and %  
Clinical Chemistry  alanine transaminase (ALT)  
aspartate transaminase (AST)  
gamma -glutamyl transferase (GGT)  
alkaline phosphatase (ALP)  
bilirubin (total and direct)  
lactate dehydrogenase (LDH)  
total p rotein  
albumin  creatine kinase (CK)  
sodium  
chloride  
potassium  
creatinine  
blood urea nitrogen (BUN)  
fasting blood glucose  
 
Routine Urinalysis  specific gravity , pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, 
nitrite, leukocyte esterase  by [CONTACT_48015] (if blood or protein is abnormal)  
Coagulation 
Parameters  International normalized ratio (INR) , PT, PTT  
Complement panel  Bb, C3a, C5a  
Other Screening Tests  • Alcohol breath test  
• Rapid SARS -CoV -2 (local laboratory testing)  
• Follicle -stimulating hormone (as needed in women of non -childbearing 
potential only)  
• Highly sensitive (urine ; serum for confirmation if needed)  human 
chorionic gonadotropin (hCG) pregnancy test (as needed for WOCBP).  
Any positive urine pregnancy test will be  confirmed with a serum 
pregnancy test.  
• Urine drug screen (to include at minimum: amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_858], and benzodiazepi[INVESTIGATOR_1651])  
• Viral serology (human immunodeficiency virus antibody, hepatitis B 
surface antigen, and hepatitis C virus antibody)  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 61 10.3. Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Fo llow-up, and Reporting  
10.3.1.  Definition of A dverse Event 
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of  study intervention, whether or not considered related to the study 
intervention. A n AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated 
with the  use of study intervention.  
Events Meeting the AE Definition  
• Any abnormal laborator y test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that wo rsen from baseline, considered clinically significant in the 
medical and scientific  judgment of the Investigator .  
• Exacerbation of a chronic or intermittent pre -existing condition , including either an 
increase in frequency and/or intensity of the condition . 
• New condition detected or diagnosed after study intervention administration , even  
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clini cal sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be  reported regardless of sequelae.  
Events NOT Meeting the AE Definition  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (soc ial and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of S erious Adverse Event 
If an event is not an AE p er definition above, then it cannot be an SAE even if serious  conditions 
are met.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50691] medical occurrence that, at any dose:  
• Results in death  
• Is life -threatening  
The term ‘life-threatening ’ in the definition of ‘serious ’ refers  to an event in which the 
participant was at risk of death at  the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.  
• Requires inpatient hospi[INVESTIGATOR_47950], hospi[INVESTIGATOR_47951] (usually involving 
at least an overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment 
that would not have been appropriate in the physician’s off ice or outpatient setting. 
Complications that occur during ho spi[INVESTIGATOR_1084]. If a complication prolongs 
hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to 
whether “hospi[INVESTIGATOR_059]” occurred or was neces sary, the AE should be considered serious.  
Hospi[INVESTIGATOR_1086] r elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.  Pre-planned hospi[INVESTIGATOR_47952], for an elective medica l/surgical procedure do not meet this criterion.  
• Results in p ersistent disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
This definition is not intended to include experiences o f relatively minor medical significance 
such as uncomplicated  headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma (e.g., sprained ankle) , which may interfere with or prevent everyday life functions but 
do not constitute a substantial dis ruption.  
• Is a congenital anomaly/birth defect  
• Other situation s: 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations , such as important medical events that may not be immediately 
life-threa tening or result in death or hospi[INVESTIGATOR_47953]. These events should usually be considered serious.  
Examples  of such events include invasive or malignant cancers, intens ive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that 
do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.  
10.3.3.  Definition of Adverse Events of Special Interest  
An AESI is a  noteworthy event for the particular product or class of products that a Sponsor may 
wish to monitor carefully (CIOMS IV, 2005).  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 63 Events Meeting the AE SI Definition  
Injection Site Reaction  
An ISR i s characterized by [CONTACT_48016] (usually immunologic) developi[INVESTIGATOR_47954] [ADDRESS_50692] ration of the study 
intervention  may cause a specific local reaction originating around t he injection site, such as 
erythema, itching, d iscomfort and pain, and could include  more severe manifestations such as 
ulceration or necrosis.  
Potential ISRs will be evaluated and recorded as follows:  
Individual signs or symptoms at the injection site wi th an onset of less than 4  hours  from the time 
of study intervention administration will be recorded as individual AEs  (bruising, itching, 
transient erythema , swelling, etc. ) and not as ISRs .  
Signs or symptoms at the injection site with a time to onset of  [ADDRESS_50693]-injection  will 
be recorded as an ISR  if any of the CTCAE criteria for ISR detailed in Table  9 are met . Signs or 
symptoms at the injection site that occur ≥ [ADDRESS_50694]-injection but are not specified in Table  9 
should be recorded as AEs . 
Table  9: Grading of Injection Site Reactio ns, CTCAE v 5.0  
Grade  1 Grade  2 Grade  3 Grade  4 Grade  5 
Tenderness with or 
without associated 
symptoms (e.g., 
warmth, erythema, 
itching)  Pain; lipodystrophy; 
edema; phlebitis  Ulceration or 
necrosis; severe 
tissue damage; 
operative 
intervention 
indicated  Life-threatening 
consequences; urgent 
intervention 
indicated  Death  
 
10.3.4.  Recording and Follow -Up of AEs and/or SAE s 
[IP_ADDRESS].  AE and SAE Recording  
When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation 
(e.g., hospi[INVESTIGATOR_47955], laboratory reports, diagnostics reports) related to the event.  
The Investigator will then record all relevant AE/SAE information in the eCRF.  
It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]'s med ical records to 
the Spon sor in lieu of completion of the AE/SAE CRF page.  
There may be instances when copi[INVESTIGATOR_47956].  In this case, all participant identifiers, with the exception of the participant  number, will 
be redacte d on the copi[INVESTIGATOR_47957].  
The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnos is (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 64 [IP_ADDRESS].  Assessment of Intensity  
The Investigator will make an assessment of each AE and SAE reported during the study . The 
grade of each event will be determined using CTCAE v 5.0 criteria . 
[IP_ADDRESS].  Assessment of Causality  
The Investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.  
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, r ather than a relationship cannot be ruled out.  
The Investigator will use clinical judgment to determine the relationship.  Alternative causes, 
such as concomitant therapy and other risk factors, as well as the temporal relationship of the 
event to study int ervention administration will be considered and investigated.  The Investigator 
will also consult the Investigator Brochure ( IB) and/or Product Information (for marketed 
products ) in his/her assessment.  
For eac h AE/SAE, the Investigator must  document in the  medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality.  
There may be situations in which an SAE has occurred , and the Investigator has minimal 
information to include in the initial report . However, it is very importa nt that the Investigator 
always make an assessment of causality for every event before the initial transmission of the 
SAE data to SAE Coordinator.  
The Investigator may change his/her opi[INVESTIGATOR_47958] l ight of follow -up information and 
send a SAE fo llow-up report with the updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
The following definitions will be used in assessin g causality:  
• Not Related : Event for which suffi cient evidence exists to conclude that the etiology 
is unrelated to study intervention.  
• Possibly Related : There is some temporal relationship between the event and the 
administration of the study intervention,  and the event is unlikely to be explained by 
[CONTACT_2299]’s medical condition or other therapi[INVESTIGATOR_014].  
• Probably Related : The temporal relationship between the event and administration 
of the study intervention is suggestive and the event is unlikely explai ned by [CONTACT_2416]’s medical condition or o ther therapi[INVESTIGATOR_014].   
• Definitely Related : The event follows reasonable temporal sequence from 
administration of the study intervention, follows a known or suspected response 
pattern to the study intervention, is co nfirmed by [CONTACT_48017][INVESTIGATOR_47959], and reappears upon repeated exposure, if that occurs.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 65 [IP_ADDRESS].  Follow -up of AEs and SAEs  
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations  as medically indicated or as requested by [CONTACT_48018]/or causality of the AE or SAE as fully as possible. This may include 
additional laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals.  
If a participant d ies during participation in the study or during a recognized follow -up period, the 
Investigator will provide the Sponsor  with a copy of any post -mortem findings including 
histopathology.  
New or updated informa tion will be recorded in the originally complet ed CRF.  
The Investigator will submit any updated SAE data to the Sponsor  within [ADDRESS_50695] Informat ion page . 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 66 10.4. Contracepti ve Guidance and Collection of Preg nancy Information  
10.4.1.  Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
If fer tility is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be  
confirmed before administration of study intervention, additional evaluation should be 
considered.  
Women in the following categories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal with one of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oopho rectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above,  (e.g., mülle rian agenesis, androgen insensitivity), Investigator  discretion should be 
applied to determining study entry.  
Note: Documentation can com e from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history inter view.  
3. Postmenopausal  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
− A high follicle  stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not  using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation wit h more than one  FSH measurement 
is required.   
• Participants  on HRT and whose menopausal status is in doubt will be requi red to use 
one of the non -estrogen hormonal highly effective contraception methods if they wish 
to continue their HRT during the study. O therwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 67 10.4.2.  Contracepti on Guidance  
Male participants  
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to ONE of the following from Day 1 through the end of study  (EOS ) visit : 
• Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent , 
• Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <  1% per year as described in Table  [ADDRESS_50696] agree to remain abstinent from 
penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_47960] -defined time frame.  
Female partici pants  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table  10.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 68 Table  10: Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent  a 
(Failure rate of <1% per year when used consistently and correctly ) 
Combined (es trogen - and progestogen -containing) hormonal contraception associated with inhibition 
of ovulation  
• Oral  
• Intravaginal  
• Transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation  
• Oral  
• Injectable  
Highly Effective Method s That Are User Independent  a 
• Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation   
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP, and the absence of sperm has been confirmed. If 
not, an additional highl y effective method of contraception should be used.  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study interv ention. 
The reliability of sexual abstinence n eeds to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.  
a Typi[INVESTIGATOR_47961]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studie s. 
 
10.4.3.  Pregnancy Testing:  
WOCBP should only be included af ter a confirmed menstrual period and a negative highly 
sensitive urine or serum pregnancy test. If a urine test is positive, it must be confirmed with a 
serum test.  
Additional pregnancy testing should be performed as indicated in SoA ( Section  1.3). 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50697] 25 mIU/mL will be performed .  
10.4.4.  Collection of Pregnancy In formation  
[IP_ADDRESS].  Male Participants  with Partners Who Become Pregnant  
The Investigator  will attempt to collect pregnancy information on any male participant’s female 
partner who becomes pregnant while the male participant is in this study. This applies only to 
male participants who receive DCR -AUD . 
After obtaining the necessary signed informed consent from the pregnant female partner directly, 
the Investigator  will record pregnancy information on the appropriate form and submit it to the 
Sponsor  within 24 hours  of learning of the partner’s pregnanc y. The female partner will also be 
followed to determine the outcome of the pregnancy. Information on the status of the mother and 
child will be forwarded to the Sponsor . Generally, the follow -up will be no longer than 6 t o 
10 weeks following the estimated  delivery date. Any termination of the pregnancy will be 
reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
[IP_ADDRESS].  Participants Who Become Pregna nt 
The Investigator  will colle ct pregnancy information on any pa rticipant who becomes pregnant 
while participating in this study . The initial Information will be recorded on the appropriate form 
and submitted to the Sponsor  within 24 hours  of learning of a participant's pregnancy.  
The participant will be followed to d etermine the outcome of the pregnancy. The Investigator  
will collect follow -up information on the participant and the neonate , and the information will be 
forwarded to the Sponsor . Generally, follow -up will not be required  for longer than 6 to 
10 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
Whil e pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. A 
spontaneous abortion (occurring at <  22 weeks gestational age) or still birth  (occurring 
at > 22 weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy -related SAE considered reasonably related to the study intervention 
by [CONTACT_48019]  8.3.4 . While the 
Investigator  is not obligated to actively seek this information in former study participants, he or 
she may le arn of an SAE through spontaneous reporting.  
Any participant who becomes pregnant while participating in th e study will discontinue study 
intervention .  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 70 10.5. Genetics  
Use/Analysis of DNA  
• DNA samples will be used for research related to genetic allelotypes  (including 
ALDH2 ) that could potentially influence alcohol metabolism and the impact of 
DCR -AUD . Genetic resear ch may consist of the analysis of one or more candidate 
genes or the analysis of genetic markers throughout the genome potentially re lated to 
alcohol metabolism . 
• DNA samples will be analyzed for ALDH2  genotypi[INVESTIGATOR_007] . Additional  exploratory 
analyses may be cond ucted if it is hypothesized that this may help further understand 
the clinical data.  
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to DCR -AUD  or study interventions of this class to 
understand s tudy disease or related conditions.  
• The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
• The Sponsor  will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples w ill be retained while research on DCR -AUD  continues , but no longer 
than 5 years or other period as per local requirements.  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 71 10.6. Liver Safety: Suggested Actions and Follow -up Assessments  
Phase 1 liver chemistry stoppi[INVESTIGATOR_47962] t safety and to evaluate 
liver event etiology  (Table  11). 
Table  11: Liver Safety: Suggested Actions and Follow -up Assessments  
Liver Chemistry Stoppi[INVESTIGATOR_31789]/AST -
absolute  ALT or AST ≥  3×ULN  
If ALT or AST ≥  3×ULN AND  total bilirubin   2×ULN (>  35% direct bilirubin)  or 
INR > 1.5, report to Sponsor in expedited manner.a, b 
See additional actions and foll ow-up assessments below  
Required Actions, Monitoring , and Follow -up Assessments  
Actions : 
• Report the event to the CRO Medical Monitor within 24  hours  
• Complete an SAE data collection tool if the event also met the criteria fo r an SAE  b 
• Perform liver function  follow -up assessments as described in the Follow Up Assessment s below.   
• Monitor the participant until liver function test abnormalities  resolve, stabili ze, or retu rn to baselin e 
Monitoring:  
If ALT or AST ≥ 3×ULN AND total bilirubin  2×ULN or INR >  1.5 
• Repeat liver function tests  (include ALT, AST, alkaline phosphatase, total bilirubin , and INR ) 
and perform liver function follow -up assessments within  24 hours.  
• Moni tor participant  twice weekly until liver function test abnormalities  resolve, stabili ze, or 
return to baseline . 
• A specialist or hepatology consultation is recommended . 
If ALT or AST ≥ 3×ULN AND total bilirubin <  2×ULN and INR ≤  1.5: 
• Perform  liver function tests ( include ALT, AST, alkaline phosphatase, total bilirubin , and INR ) 
and perform  liver function follow -up assessments within 24 to 72 hours 
• Monitor participant s weekly until liver function abnormalities  resolve, stabilize , or return to 
baselin e 
Follow -Up Assessments  
• Viral hepatitis sero logy (includes: Hepatitis A immunoglobulin M [IgM] antibody; HBsAg and 
HBcAb; hepatitis C RNA; cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM 
antibody [or if unavailable, heterophile antibody or mon ospot testing ]; and hepatitis E IgM 
antibody )  
• Obtain s erum CK, LDH, GGT, GLDH , and ser um albumin  
• Fractionate bilirubin, if total bilirubin   2×ULN  
• Obtain c omplete blood count with differential to assess eosinophilia  
• Record the appearance or worsening of c linical symptoms of liver injury, or hypersensitivity, on 
the eCRF  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 72 • Record use of concom itant medications or ingestions (including wild mushrooms, acetaminophen, 
herbal remedies, recreational drugs, and other over -the-counter medications). Note any 
concomit ant medications that have been recently initiated or for which doses have increased.  
• Record alcohol use on the  eCRF  
If ALT or AST ≥ 3×ULN AND total bilirubin  2×ULN or INR >  1.5 obtain the following in 
addition to the assessments listed above : 
• Anti-nuclea r antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total immunoglobulin G ( IgG) or gamma globulins  
• Liver imaging (ultrasound, magnetic resonance, or computeri zed tomography) and /or liver 
biopsy to eval uate liver disease  
• Liver biopsy may be considered and discussed with local s pecialists if available , for instance:  
− When serology raises the possibility of autoimmune hepatitis (AIH)  
− When suspected DILI progresses or fails to resolve on withdrawal of study  intervention  
− In pa rticipants with acute or chronic atypi[INVESTIGATOR_31790].  
 
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study intervention if ALT ≥  3×ULN and total bilirubin ≥  2×ULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record the absence/presence of detectable 
urinary bilirubin on dipstick which is indicat ive of direct bilirubin elevations suggesting liver injury.  
b All events of ALT ≥  3×ULN and total bilirubin ≥  2×ULN (>  35% direct bilirubin) or ALT ≥  3×ULN and 
INR > 1.5 may indicate severe liver injury (possible ‘Hy’s Law’) and must be reported to sponsor in an exped ited 
manner and as an SAE if SAE criteria met (excluding studies of hepatic impairment or cirrhosis).  
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 73 10.7. Abbreviations  
Abbreviation  Description  
ADA  antidrug antibody(ies)  
AE adverse e vent 
AESI  AE of special interest  
ALDH2  aldehyde dehydrogenase [ADDRESS_50698]  aspartate aminotransferase  
AUC  area under the curve  
AUD  alcohol use disorder  
BAC  blood alcohol concentration  
BMI  body mass index  
BP blood pressure  
bpm beats per minute  
BUN  blood urea nitrogen  
°C degrees Celsius  
CFR  Code of Federal Regulations  
CFU  conditional follow -up 
CIOMS  Council for International Organizations of Medical Scienc es 
CK creatine kinase (creatine phosphokinase)  
CL clearance  
Cmax maximum observed concentration  
Cmin minimum observed concentration  
CONSORT  Consolidated Standards of Reporting Trials  
CRO  contract research organization  
CSR  clinical study report  
C-SSRS Columbia -Suici de Severity Rating Scale  
CTCAE  Common Terminology Criteria for Adverse Events  
CV%  coefficient of variation (percent)  
DCR -A1203 drug substance for this IMP  
DLT  dose-limiting toxicity  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 74 Abbreviation  Description  
DS drug substance  
DSMC  Data Safety Monitoring Commi ttee 
ECG  electrocardiogram  
eCRF  electronic case report form  
e.g. for example ( exempli gratia ) 
EIA ethanol interaction assessment  
EOS  end of study  
EOT  end of treatment  
EtOH  ethyl alcohol  
FDA  Food and Drug Administration  
FIH first-in-human  
FSH follicle stimulating hormone  
GABA  gamma -aminobutyric acid  
GalNAc  N-acetylgalactosamine  
GCP  Good Clinical Practice  
GGT  gamma glutamyl transferase  
GI gastrointestinal  
GLP  Good Laboratory Practice  
HbA1c  hemoglobin A1c  
HBsAg  hepatitis B surface antigen  
hCG human chorionic gonadotropin  
HCV  hepatitis C virus  
HIPPA  Health Insurance Portability and Accountability Act  
hr hour(s)  
HIV human immunodeficiency virus  
HRT  hormone replacement therapy  
HV healthy volunteer  
IA interim analysis  
IB Investigator’s B rochure  
ICF informed consent form  
ICH The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 75 Abbreviation  Description  
i.e. that is ( id est ) 
IEC Independent Ethics Committee  
IMP Investigational Medicinal Product  
INR internatio nal normalized ratio  
IRB Institutional Review Board  
ISR injection site reaction  
ITT Intent to treat  
IUD intrauterine device  
IVRS/IWRS  Interactive Voice/Web Response System  
IUS intrauterine hormone -releasing system  
kg kilogram(s)  
LDH  lactate dehydro genase  
LFT liver function test  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MINI  Mini International Neuropsychiatric Interview  
miRNA  micro -RNA  
mRNA  messenger ribonucleic acid  
mg milligra m(s) 
min minute(s)  
mL milliliter(s)  
mRNA  messenger ribonucleic acid  
M&S  modeling and simulation  
NOAEL  no observed adverse effect  level  
NPO  nothing by [CONTACT_48020] -inflammatory drug  
OTC  over the counter  
PD pharmacodynamic(s)  
PK pharmacokinetic  
PI [INVESTIGATOR_47963] (Fridericia correction)  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50699] deviation  
SEAS Subjective Effects of Alcohol Scale  
siRNA  small interfering RNA  
SoA schedule of activities  
SRC  Safety Review Committee  
SUD  Substance abuse disorder  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t1/[ADDRESS_50700] infection  
Vd/F apparent volume of distribution  
WFI water for injection  
WOCBP  woman(en) of childbearing potential  
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 77 10.8. Investiga tor Signature [CONTACT_3490]  
 
A Phase  1, Double -blind, Placebo -controlled, Single -ascending -dose, Safety, Tolerability, 
Pharmacokinetics, and Pharmacodynamics Study of DCR -AUD in Healthy Volunteers  
 
Protocol Number:  DCR -AUD-101 
Version:  6.0 
Date:  14-Mar-[ADDRESS_50701] this trial in accordance with all stipulations of the 
protocol and in accordance with Good Clinical Practice (GCP) guidelines, the Declaration of 
Helsinki, and local regulations (as applicable).  
 
 
Signature:   [CONTACT_1782]: 
Name:   [CONTACT_1641]:  
Institution:   Site Number:  
 
  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 78 10.9. Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.  
 
Amendment 5: 14-Mar -2022  
Overall Rationale for Amendme nt 5: 
The [ADDRESS_50702] of the interim 
analysis scheduled at the conclusion of Cohort 2, as emerging PD data did not dictate it was 
warranted. Other points of clarification for the timing and scheduli ng of study visits were also 
added .  
 
Amendment 4: 28-Jul-2021  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union . 
Overall  Ratio nale for the Amendment:  
The 26-Jul-2021 version of the protocol  was amended to address the concerns and questions 
raised by [CONTACT_48021]  3 of the protocol .  
Protocol Amendment 4 Summary of Changes  
Description of Change  Brief Rationale  Affected Sections  
Added group mean AUC 0-48 and 
Cmax values from the 100 mg/kg 
dose in the [ADDRESS_50703] new version  Throughout the protocol  
 
Amendment 3: 26 -Jul-2021  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union . 
Overall Rationale for the Amendment:  
The 19-Jul-2021 version of the protocol  was amended to address the concerns and questions 
raised by [CONTACT_48021]  2 of the protocol .  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 79 Protocol Ame ndment 3, Summary o f Changes  
Description of Change  Brief Rationale  Affected Sections  
Added PK stoppi[INVESTIGATOR_47964] C max values observed at the 
mid-dose in the 5 -week monkey 
toxicology study (Study Number 
20-A1203 -P-030) and to align with 
FDA input by [CONTACT_41680] a more 
conservative approach to safety 
margins  2.2.2  Nonclin ical Overview of 
DCR -AUD  
2.3.1 Risks Related to siRNA 
Molecules  
4.3 Justification for Dose  
6.1.1  Dose Levels and Dose 
Escalation  
6.5 Dose Modification  
7.3 Cohort Stoppi[INVESTIGATOR_1869]  
9.6 Safety Review Committee  
11 References  
Added assessment of 
complement level s (Bb, C3a, 
C5a) and revised maximum 
planned blood volume to be 
drawn  To monitor for potential 
immunostimulatory effects  1.3 Schedule of Activities  
2.3.1  Risks Related to siRNA 
Molecules  
2.3.4  Risk Assessment  
8 Study Assessments and 
Procedures  
10.2 Clinical Laboratory Tests 
(Table 8)  
Added CFU for participants with 
ethanol reaction symptoms at 
Day [ADDRESS_50704] no 
residual IP -related symptoms from 
EIA 1.1.3  Overall Design  
1.2 Study Schema  
1.3 Schedu le of Activities  
2.3.4  Risk Assessme nt  
4.1 Study Design  
8.3.1  Time Period and Frequency 
for Collecting Adverse Event 
Information  
[IP_ADDRESS]  Follow -up of Participants 
Who Continue to Have 
Positive Ethanol Reaction 
Symptoms at Day [ADDRESS_50705] 
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 80  
Amendment 2: 19 -Jul-2021  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment:  
The 09-Jul-[ADDRESS_50706] Info rmation  
Corrected error in study schema 
that V3 is on Day 29  To ensure schema aligns with 
schedule of assessments  1.2 Figure 1  
Specified blood pressure criteria for 
eligibility range of 90-140 mmHg 
systolic and 55 -95 mmHg diastolic  To ensure participant s’ BPs are 
neither too high nor too low  5.1 Inclusion criteria  
5.2 Exclusion criteria  
[IP_ADDRESS]  Stoppi[INVESTIGATOR_47965] 
> 20 bpm or to a level of >  100 bpm 
would prompt stoppage of EIA  To ensure participant safety  [IP_ADDRESS]  Stoppi[INVESTIGATOR_47966]  5.2 Exclusion criteria  
7.1 Participant 
Discontinuation/Withdraw al 
from the Study  
8.7.1  Ethanol Interaction 
Assessment  
Added statement about required 
overnight stay in the Phase  1 unit 
after EIA and that participants will 
not be discharged until deemed 
medically safe  To ensure part icipant safety  8.7.1  Ethanol Interaction 
Assessment  
Added clarifications about Day  -1 
alcohol exposure, which is not part 
of an EIA assessment  To emphasize the predose 
exposure to alcohol to ensure 
eligibility and establish baseline 
for biomarker assessme nts 1.1.3  Overall Design  
1.3 Footnote “n” of Table 1  
4.2 Scientific Rationale for Study 
Design  
 
 
Amendment 1: 09-Jul-2021  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the Europe an Parliament and the Council of the European Union.  
Overall Rationale for the Amendment:  
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 81 The 24-Jun-2021 version of the protocol  was amended  to address the c oncerns and questions 
raised by [CONTACT_48022][INVESTIGATOR_47967].  
Protocol Amendment 1, Summar y of Changes  
Description of Change  Brief Rationale  Affected Sections  
Provided additional 
information about placebo  Specified physiologic saline (0.9% 
aqueous sodium chloride) would be 
used for placebo  6.1.1  Dose Levels and Dose  
Escalation (Table 5)  
6.2.3  Preparation and Administration  
Added use of the Mini 
International 
Neuropsychiatric Interview 
(MINI) 7.0.[ADDRESS_50707] results will be 
used to determine eligibility  To ensure par ticipant safety  5.2 Exclusion Criteria  
Clarified instructions about 
treatment administration  Specified that for dose levels requiring 
>1 injection, treatment would be 
administered by [CONTACT_48023]  6.2.3  Preparation and Administratio n 
Made all physical 
examinations full 
examinations  Eliminated option for brief physical 
examinations for clarity  1.3 Schedule of Activitie s 
8.2.1  Physical Examinations  
Clarified documentation of 
start date of AEs and SAEs 
and defined start date of 
TEAE  All AEs and SAEs will be collected 
after signature [CONTACT_48028]. AEs will be 
defined as treatment -emergent if they 
occur after administration  of study 
intervention.  7.3 Cohort Stoppi[INVESTIGATOR_1869]  
9.4.2  Primary Endpoint(s)  
Clarified SAE, DLT, and 
study stoppi[INVESTIGATOR_47968] a FIH study, so all AEs, SAEs, 
and DLTs will considered at least 
possibly related unless clearly a result 
of a non -study related event.  7.3 Cohort Stopp ing Rules  
7.3.1  Dose Limiting Toxicities  
7.4 Study Stoppi[INVESTIGATOR_47969] a FIH study, so removed 
references to disease progression as 
this is not applicable.  8.2.7  Clinical Safety Laboratory 
 Assessments  
10.3.1  Definition of Adverse Event  
10.3.2  Definition of Serious Adverse 
 Event  
[IP_ADDRESS]  Assessment of Causality  
10.5 Genetics  
Increased requirement for 
contraceptive use from 12 to 
24 weeks  Increased requirement of 
contraceptive use to cover the full 
duration of the study.  5.1 Inclusion Criteria  
8.3.5  Pregnancy  
10.4.2  Contraception Guidance  
Added summary of changes 
for Amendment 1 (dated 
09-Jul-2021)  For clarity   
 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -[ADDRESS_50708] cancer. Biophys Rev. 2018 
Feb;10(1):69 -86. 
Bae KY, Kim SW, Shin HY, Kim JM, Shin IS, Kim SJ, et al. The acute effects of ethanol and 
acetaldehyde on physio logical responses after ethanol ingestion in young healthy men with 
different ALDH2 genotypes. Clin Tox. 2012 Apr 1;50(4):242 -9. 
Bryson WC, McConnell J, Korthuis PT, McCarty D. Extended -release naltrexone for alcohol 
dependence: persi stence and healthcare costs and utilization. Am J Manag Care. 2011 Jun;[ADDRESS_50709] 8:S222 -34.  
Campral® (acamprosate calcium)  [package insert] . Revised Jan 2012.  St. Louis, MO:  Forest 
Pharmaceuticals, Inc.  Available at : 
https://www.accessdata.fda.gov/drugsatf da_docs/label/2012/021 431s015lbl.pdf . 
Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, et al. Disulfiram t reatment of  
alcoholism. Br J Psychiatry. 1992 Jul;161:84 -9.  
Cooper GM, Brudno M, NISC Comparative Sequencing Program, Green ED, Batzoglou S, 
Sidow A.  Quantitativ e estimates of sequence divergence for comparative analyses of mammalian 
genomes. Genome Res . 2003; 13:813 -20. 
Dicerna Pharmaceuticals, Inc. “Our GalXC™ Technology Platform ”, April 2020, Available from: 
http://dicerna.com/o ur-technology/dicernas -delivery -platforms/. Accessed 20 October 2020.  
EMA/CHMP/EWP/[ZIP_CODE]/2008 (previously EMEA/CHMP/EWP/[ZIP_CODE]/2008). Committee for  
Medicinal Products for Human Use (CHMP). Guideline on the development of medicinal 
products for the treatment  of alcohol dependence. 18 February 2010.  
Eng MY, Luczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature  
review. Alcohol Res Health. 2007;30(1):22 -7.  
Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different al dehyde  
dehydrogenase -2 genotypes. Alcohol Clin Exp Res. 1991;15(1):[ADDRESS_50710] of an RNA interference drug on the synthesis of proprotein convertase 
subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy 
volunteers: a randomised, single -blind, placebo -controlled, phase 1 trial. Lancet. 2014 Jan 
4;383(9911):[ADDRESS_50711];1327:112 -30.  
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epi[INVESTIGATOR_47970] -5 
Alcohol Use Disorder: Results from the National Epi[INVESTIGATOR_47971]. JAMA Psychiatry. 2015 Aug;72(8):757 -66. 
Han B, Hedden SL, Lipari R, Copello EA, Kroutil LA. Receipt of services for behavioral health 
problems: Results from the 2014 National Survey on Drug Use and Health. Rockvill e, MD: 
Substance Abuse and Mental Health Services Administration. 2015 Sep. Available from: 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 83 https://www.samhsa.gov/data/report/receipt -services -behavioral -health -problems -results -2014 -
national -survey -drug-use-and-health.  
Huang Y. Preclinical and clinical a dvances of GalNAc -decorated nucleic acid therapeutics. Mol  
Ther Nucleic Acids. 2017 Mar 17;6:[ADDRESS_50712];35(10):1749 -58.  
Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: 
from concept to clinical r eality. Genome Med. 2017 Jun 27;9(1):60.  
Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in 
addiction treatment p rograms. J Addict Med. 2011 Mar;5(1):21 -7.  
Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO,  et al. Aldehyde  
dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, 
substrate specificity, and clinical  application. Pharmacol Rev. 2012 Jul;64(3):520 -39. 
Litten RZ, Falk D, Ryan M, Fertig J. Research opportunities f or medications to treat alcohol 
dependence: addressing stakeholders ’ needs. Alcohol Clin Exp Res. 2014 Jan;38(1):27 -32.  
Morean ME, Corbin WR, Treat TA. The subje ctive effects of alcohol scale: development and 
psychometric evaluation of a novel assessment tool for measuring subjective response to alcohol. 
Psychol Assess. 2013 Sept;25(3):doi:10.1037/a0032542.  
National Cancer Institute [Internet].  Bethesda (MD): National Cancer Institute (US); Common 
Terminology Criteria for Adverse Events Version 5.0. ; [cited 201 9 Mar 22]. Available from:  
https://ctep.cancer.gov/ protocolDevelopment/ electronic_applications/ docs/
CTCAE_v5_Quick_Reference_5x7.pdf . 
Nishimura FT, Fukunaga T, Kajiura H, Umeno K, Takakura H, Ono T, Nishijo H. Effects of 
aldehyde dehydrogenase -2 genotype on cardiovascular and endocrine responses to alc ohol in 
young Japanese subjects. Auton Neurosci. 2002;102:[ADDRESS_50713] alcoholism i n Asians, heterozygous for the variant ALDH2*2  
gene allel e. Pharmacogenetics and Genomics. 2007;17(10):[ADDRESS_50714] alcoholism by [CONTACT_48024]. Pharmacogenetics. 1999;9:463 -76. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia -
Suicide Severity Rating Scale: initial validit y and internal consistency findings from three 
multisite studies w ith adolescents and adults. Am J Psychiatry.  2011 ; 168(12):[ADDRESS_50715], et al. Dynamic 
PolyConjugates for targeted in vivo delive ry of siRNA to hepatocytes. Proc Natl Acad Sci U S  
A. 2007 Aug 7;1 04(32):[ZIP_CODE] -7. 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini -
International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a 
DocuSign Envelope ID: 

Dicerna Protocol DCR -AUD -101  Version 6.0, 14-Mar-2022  
 Page 84 structured diagnostic psychiatric interview for DSN -IV and ICD -10. J Clin Psychiatr y. 1998; 
59[Suppl 20]:22 -33.  
Sobell  LC, Sobell  MB. Timeline follow -back: A technique for assessing self -reported alcohol 
consumption. In: Litten  RZ, Allen JP, e ditors. Measuring alcohol consumption: psychosocial and 
biochemical metho ds. Washington DC: Ame rican Psychological Association. 1992 . pp. 41-72. 
Substance Abuse and Mental Health Services Administration, Results from the 2013 National 
Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H -48, HHS 
Publication No. ( SMA) 14 -4863. Ro ckville, MD: Substance Abuse and Mental Health Services 
Administration, 2014.  Available from: https://www.samhsa.gov/data/sites/default/files/
NSDUHresultsPDFWHTML2013/ Web/ NSDUHresults2013.pdf . 
U.S. Food and Drug Administration , Center for Drug Evaluation and Research. Guidance for  
Industry : Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics 
in Adult Healthy Volunteers.  July 2005. Available from 
https://www.fda.gov/media/[ZIP_CODE]/download . 
Vivitrol ® [package insert ]. Revised  July 2020 . Alkermes, Inc.  Available at:  
https://www.vivitrol.com/content/pdfs/prescribing -information.pdf .  
Wittrup A, Lieberman J. Knocking  down disease: a progress report on siRNA therapeutics. Nat 
Rev Genet. 2015;16(9):543 –52. 
DocuSign Envelope ID: 
